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ABSTRACT OF DISSERTATION 
 
 
DEVELOPMENT OF NOVEL AHR ANTAGONISTS 
Aryl hydrocarbon receptor (AHR) is a sensor protein, activated by aromatic 
chemical species for transcriptionally regulating xenobiotic metabolizing enzymes.  AHR 
is also known to be involved in a variety of pathogenesis such as cancer, diabetes mellitus, 
cirrhosis, asthma, etc.  The AHR signaling induced by xenobiotics has been intensively 
studied whereas its physiological role in the absence of xenobiotics is poorly understood.  
Despite a number of ligands of AHR have been reported thus far, further applications are 
still hampered by the lack of specificity and/or the partially agonistic activity.  Thus, a 
pure AHR antagonist is needed for deciphering the AHR cryptic as well as potential 
therapeutic agent.  The Proteolysis Targeting Chimera (PROTAC) is a bi-functional small 
molecule containing a ligand and proteolysis inducer.  PROTAC recruits the target 
protein to proteolysis machinery and elicits proteolysis.  Thus far, a number of PROTAC 
have been prepared and demonstrated to effectively induce the degradation of targeted 
protein in cultured cells, validating PROTAC as a useful research tool. In the present 
study, PROTACs based on apigenin was prepared and demonstrated to induce the 
degradation of AHR, providing the proof of concept.  To improve activity, a synthetic 
structure, CH-223191, was optimized for antagonistic activity by positional scanning 
identifying several AHR antagonists.  PROTACs based on the optimal structure were 
prepared and assessed their biological activity. The products and synthetic scheme 
described hereby will be helpful for the further understanding on AHR biology as well as 
for developing therapeutic agents targeting AHR. 
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optimization, ubiquitin proteasome system, UPS. 
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CHAPTER 1 OVERVIEW 
 
With the advent of the proteomics era, elucidation of protein function is of great 
importance in developing novel therapeutic agents and dissecting complex signaling 
pathways. While a number of useful approaches have been used to investigate the 
function of proteins, their applications are often limited due to difficulties with temporal 
and spatial control of protein function. Furthermore, these approaches are also 
constrained to a certain subset of signaling molecules.   
Traditionally, small molecules have played a crucial role in the drug development 
process by providing lead compounds.  In recent years, small molecules have been 
increasingly serving an additional purpose as a molecular probe in investigating 
principles underlying biology.  Therefore, the development of novel chemical agents 
modulating protein function has become of more importance in elucidating the role of 
proteins in biological processes. 
Proteolysis Targeting Chimera (PROTAC) is a novel class of small molecules that 
target proteins of interest for degradation.  PROTACs recruit targeted proteins to E3 
ubiquitin ligase complex for ubiquitination and subsequent degradation by the 
proteasome.  Up to the present time, a number of proteins have been successfully targeted 
for degradation by the PROTAC approach (1-5), validating the PROTAC approach as a 
novel tool for perturbing protein function.  AHR is a ligand-activated transcription factor, 
regulating the metabolism of xenobiotics (6).  Even though considerable effort has been 
devoted to the study of the roles of AHR in human physiology, the knowledge gained 
from these studies is still limited due to the lack of appropriate molecular tools.  In 
addition, emerging data suggest that AHR may play a role in disease development and 
progression.  Furthermore, recent studies indicate that AHR is a potentially therapeutic 
target.  Therefore, the development of novel molecular tool that can modulate AHR 
function is urgently needed to investigate the complex AHR biology as well as to validate 
the AHR as a therapeutic target.  With these in mind, we envision that AHR-targeting 
PROTACs and the synthetic procedures will provide useful molecular tools as well as a 
lead compound to be used for further development of AHR-targeting therapeutic agents. 
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Specific Aims 
 
The overall goal of this study is to develop a novel antagonist of the aryl 
hydrocarbon receptor (AHR) as a research tool to explore AHR biology as well as a 
potential therapeutic agent.  The rationale underlying the proposed study was based on 
the fact that there is no pure AHR antagonist currently available for use of dissecting the 
complex AHR biology.  Further, the PROTACs may provide potential therapeutic agents 
by targeting disease-promoting proteins.  Taken together, we hypothesized that AHR-
targeting PROTAC will provide a pure and specific antagonist of AHR.  To test this, the 
following specific aims were set forth:  
 
1) Determine whether the AHR is targeted by the PROTAC approach  
A number of phytochemicals were identified as AHR antagonists.  Among these, 
apigenin and kaempferol were selected for the synthesis of PROTAC.  The SAR study of 
apigenin revealed that derivatization at hydroxyl groups of apigenin is tolerated for its 
AHR antagonistic activity.  Thus, PROTACs were prepared by linking E3 ligase 
recognition residue at the 4‟ hydroxyl group of apigenin and tested for their activity of 
AHR degradation. Similarly, kaempferol-based PROTACs were prepared and tested for 
their activity. 
 
2) Identify AHR additional antagonists by constructing and screening a chemical library 
Despite the promising potential of the apigenin-based PROTAC, its target 
specificity is a major concern due to apigenin‟s multiple targets in cells.  Therefore, we 
aim to develop specific AHR ligands and prepare PROTACs based on the specific AHR 
ligands. To develop specific AHR antagonists, we have built a small molecule library 
using the core structure of a known synthetic AHR antagonist, CH-223191 and have 
identified a number of AHR ligands.  
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3) Develop synthetic AHR antagonist-based PROTACs  
Synthetic antagonist-based PROTACs were synthesized by introducing a „handle‟ 
at the several positions of AHR ligands selected above. To optimize AHR degradation, 
several PROTACs with varying linker lengths were prepared.  
 
4) Determine the activity of PROTACs in living cells.   
Using Western blot, we investigated the ability of PROTACs to degrade the AHR. 
In addition, it was examined whether PROTACs inhibit TCDD-induced AHR 
transcriptional activation. Further, the transcription of downstream genes was 
investigated using RT-PCR.   
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CHAPTER 2 INTRODUCTION 
 
 
2.1 Aryl hydrocarbon Receptor 
 
AHR is a ligand activated transcription factor, which is classified as a member of 
the basic helix-loop-helix/Per-Arnt-Sim (bHLH/PAS) family (7).  AHR has long been 
recognized to mediate the toxic effects of exogenous chemical agents, including 
polycyclic and halogenated aromatic hydrocarbons (8-13).  Recently, additional functions 
of AHR have been reported.  Recent data indicates that AHR is implicated in cell cycle 
regulation, reproduction, development, circadian rhythm, and immune response by 
playing a pivotal role in key signaling networks.  Hence, it has been suggested that the 
perturbation of this network by this xenobiotic chemical agent may cause toxicity and 
diseases (14). 
 
 
Figure 2.1 Functional domains of Aryl hydrocarbon Receptor 
 
 
AHR protein is comprised of a number of functionally distinctive domains, the 
DNA binding domain in the N-terminal (15, 16), ligand binding domain in the middle (17, 
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18) and transactivational domain in the C-terminus (19).  The DNA binding domain of 
AHR is contained within the bHLH region and PAS regions are responsible for the 
interaction with aryl hydrocarbon receptor nucleus translocator (ARNT) (20) (17, 18).  
AHR has two PAS consensus domains, PAS-A and PAS-B (17, 21).  The PAS domains 
support the PAS-PAS interaction for dimerization with ARNT (17, 18).  The PAS-B 
contains ligand binding site that initiates the signaling pathways transduction (22).  The 
glutamine rich region (QRR) is located in the C-terminal region and supports recruitment 
of co-activator for transcriptional activation (23, 24).  The nucleus localization sequence 
(NLS) is located in the bHLH motif and is responsible for the trafficking of AHR into 
nucleus (25-27).  
 
 
2.1.1 Signaling pathway 
 
In cells, an inactive AHR is bound to a chaperone complex consisting of a dimer 
of Heat Shock Protein 90 (HSP90),  hepatitis B virus X-associated protein 2 (XAP2),  
aryl hydrocarbon receptor activated 9 (ARA9) and prostaglandin E synthase 3 (p23) (28).  
The complex protects AHR from proteolysis, prevents premature binding of ARNT and 
helps the ligand bind to AHR.  Upon binding of ligand to an inactive AHR complex, 
XAP2 and ARA9 are released from the complex exposing the NLS, leading translocation 
of AHR into the nucleus (26, 29).  Once in the nucleus, activated AHR is released from 
the complex exposing PAS domains resulting in dimerization with ARNT and binding to 
responsive elements for gene regulation (18, 30).  
The recognition motif of the AHR/ARNT dimer is the xenobiotic responsive 
element (XRE).  It is also referred to as TCDD responsive element (DRE) or AHR 
responsive element (AHRE).  A large number of genes are regulated by the interaction of 
AHR with XRE resulting in a wide variety of end results, highlighting the importance of 
AHR in physiology. While XRE is extensively characterized, the second type of XRE 
(AHRE-II) is recently identified and is thought to regulate an additional set of genes (31). 
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Though the ligand binding of AHR triggers the signaling pathways, other factors also 
contribute to the regulation of the AHR transcriptional activity.  For example, protein 
kinase C activity is required for the transcriptional activity of AHR (32).  In summary, 
the activation of AHR-mediated signaling pathways is regulated by several signaling 
factors, suggesting that various signaling pathways plausibly converge into the AHR-
mediated gene regulation.  
 
 
2.1.2 The functions of AHR in cells 
 
The general role of AHR has long been known as a master regulator of xenobiotic 
metabolizing enzymes (XMEs).  The activation of AHR pathway up-regulates the 
expression of genes involved in xenobiotic metabolism,  such as cytochrome p450 1A1 
(CYP1A1), cytochrome p450 1A2 (CYP1A2), cytochrome p450 1B1 (CYP1B1),  
aldehyde dehydrogenase 3A1 (ALDH3A1), NADPH-quinone-oxidoreductase (NQO), 
and the phase II conjugating enzymes glutathione-S-transferase A1 (GSTA1) and UDP-
glucuronosyltransferase 1A2 (UGT1A2) (33).  
AHR signaling pathway is triggered by a class of chemical agents, termed aryl 
hydrocarbons.  Generally, the ligand which triggers AHR signaling pathway is the target 
of the AHR-regulated gene products, including XMEs.  Therefore, it is thought that the 
metabolism of the ligand is the primary role of AHR.  However, the identification of 
additional genes regulated by AHR, such as TGFα, p27Kip1, COX-2 and an inhibitor of 
the TGF-β signaling pathway (latent TGF-β binding protein: LTBP-1) indicate that the 
AHR function is multifaceted (34-39).  In addition, some mitogen-activated kinases 
(MAPKs) related to cell cycle regulation, such as extracellular signal-regulated kinases 
(ERKs), c-Jun N-terminal protein kinases (JNKs) and p38, have been shown to cross-talk 
with the AHR signaling pathway (40-42).  In addition, un-anticipated functions of AHR 
have been reported, such as induction of estrogen receptor α (ERα) ubiquitination and 
degradation (43). The regulatory function of AHR with respective to the immune 
response has also been reported (44-46).  Furthermore, the role of AHR is also reported 
in developmental process of the heart, brain, and liver (47-50).  The level of AHR 
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culminates between postnatal day (PND) 3-10, this period is critical for the development 
of cerebellar granular neuroblasts (50).  The complete closure of fetal specific shunts is 
important for the proper development of heart and liver.  The cardiomyopathy and 
vascular hypertrophy were observed in AHR knocked-out animal and liver hypotrophy 
was observed as well.  These anomalies are thought to be due to the incomplete closure 
of the fetal specific shunts, ductus arteriosus, foramen ovale, and ductus venosus (48, 51).  
Ductus arteriosus is a shunt connecting the pulmonary artery to aorta and foramen ovale 
is a hole between the right and left atriums.  The fetus acquires the oxygenated blood 
from umbilical vein, hence the pulmonary circulation is not required and the fetus 
develops these shunts.  They protect the lung and allow the left ventricle to strengthen.  
The failure to close these shunts elicits hypertrophic cardiomyopathy (52).  Ductus 
venosus is a shunt bypassing the liver from the placenta to the inferior vena cava.  It helps 
the nourished and oxygenated blood flow directly to the fetal brain.  The incomplete 
closure of this shunt interrupts the liver development resulting in the liver hypotrophy 
(53).  Various anomalies have been reported in AHR knock out animal such as the T cell 
deficiency and insulin resistance as well (48).  
Taken together, it is clear that the role of AHR in tissue homeostasis and 
development process is diverse.    However, the detailed mechanistic understanding 
underlying the role of AHR in cells is yet to be fully understood. 
 
 
2.1.3 Clinical implication of AHR 
 
As aforementioned, the AHR is involved in many crucial biological processes.  
Due to its ligand-activated nature, it is presumed that the dysregulation of AHR pathways 
will disrupt signaling network, resulting in pathophysiological conditions.  Given that the 
AHR is widely known to mediate the toxicity of xenobiotics, the correlation between 
chemical compounds produced by human activities and their physiological consequences 
have been intensively studied.  In this regard, many studies have shown that anomalies in 
AHR signaling pathway can result in cancer, hyperreactivity, hydronephrosis, diabetes 
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mellitus, cirrhosis, cleft palate, and the other developmental failures such as patent ductus 
arteriosus (53-58).  
Cancer, hyperreactivity and hydronephrosis are thought to be arisen from 
inappropriate activation of AHR while other anomalies are caused by failure of AHR 
activation.  The exposure to environmental factors are thought to be, at least in part, 
responsible for many cancers and a series of studies revealed that lung cancer is more 
prevalent in populations exposed to certain chemical agents, such as  polycyclic, 
polychlorinated aromatic hydrocarbons that are commonly found in diet, tobacco smoke 
and outdoor air pollution (59).   
The metabolism of exogenous chemicals has been extensively studied, showing 
the pivotal role of AHR in metabolic pathway and carcinogenesis.  For example, the 
activation of proto-oncogene was observed upon the activation of AHR (60).  In addition, 
it was reported that AHR-mediated formation of a reactive metabolite of benzo[a]pyrene 
provides initiation step of carcinogenesis by facilitating formation of a DNA adduct (61).  
Furthermore, inactivation of tumor suppressor p53 by these metabolites was also reported 
(62).  Finally, the DNA-ligand adduct formation in carcinogenesis process was reported 
to be suppressed in AHR knock-out mice (63), indicating that the AHR may be a 
potential therapeutic target for the treatment of cancer.  
 The better understanding and the development of therapeutic agent for these 
diseases with respect to the abnormal activation of AHR are currently hampered mainly 
due to the lack of appropriate research tools.  Novel antagonists developed in this study 
may be useful molecular probes that can be used to dissect complex AHR signaling 
pathways triggered by environmental carcinogens and in other pathogenesis.  Further, the 
novel antagonists developed in the present study may be useful to test whether AHR is a 
clinical target not only for chemoprevention but also for treatment of related diseases.  
 
 
  
10 
 
2.2 Chemical approach to AHR biology 
 
 The XMEs and AHR signaling pathway are important for the adaptive response to 
exogenous chemicals.  The promiscuous ligand binding of AHR has been playing a 
crucial role in deciphering the complex signaling pathway providing the key 
understandings on the fundamental principles underlying xenobiotic metabolism.  
Paradoxically, the promiscuity hampers the development of appropriate ligands with 
antagonistic activity.  Since the pathway was immediately activated by a wide variety of 
aromatic chemicals for the gene regulation, studies on AHR have been focused on the 
effect of potent agonist which may veil the diverse consequences resulting from the weak, 
a perhaps more physiologically relevant activation of AHR.  Currently, studies on AHR 
focus more on the effect of non-classic and relatively weak agonist and/or antagonist.  
Since the physiological consequence of AHR activation is divergent and specific to the 
ligand, the development of novel ligands with more diverse structures and novel 
antagonist without agonistic potency is essential to decipher the AHR cryptics.  
 
 
2.2.1 Agonistic ligands of AHR 
 
Thus far, a large number of chemical compounds have been identified as ligands 
interacting with AHR.  Generally, these ligands are structurally related.  They are 
environmentally and biologically persistent, induce a common spectrum of responses and 
have a common mechanism of action (64).  The exogenous ligands, aryl hydrocarbons, 
are relatively well-analyzed due to the strong binding affinity, providing the structural 
understanding for binding and activation of AHR.  Recent studies demonstrated that 
structurally diverse chemicals interact with AHR, suggesting that AHR presumably has a 
promiscuous binding site(s).  Moreover, emerging studies demonstrated that 
physiological consequences of AHR activation are differentiated in a ligand-specific 
manner, highlighting the importance of understanding the structural specificity of AHR 
ligand binding. 
11 
 
AHR ligands can be categorized into two classes, synthetic and natural products.  
Most of the known ligands with high affinity belong to the first class.  This class includes 
benzo[a]pyrene, polychlorinated dibenzo-p-TCDDs (PCDDs), polychlorinated 
dibenzofurans (PCDFs), polychlorinated biphenyls (PCBs) and related compounds, such 
as 2,3,7,8 tetrachlorodibenzo-p-TCDD (TCDD) comprising “classical ligands” as termed 
by Denison et Al (65).  As the structures of recently identified ligands are substantially 
different from the classical ligands, these new synthetic AHR can be classified as “non-
classical synthetic ligands” also termed by Denison et al (65).  The overall biological 
activity and the binding affinity of non-classical ligands are not comparable to the 
classical ligands such as TCDD.  However, the identification of these non-typical 
synthetic ligands have broadened the structural spectrum of ligands to a wide diversity, 
suggesting that the chemical structure of ligands should not be restricted to the rigid 
structure based on the observation in classical ligand.  
 
Figure 2.3 Classic synthetic ligands of AHR 
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AHR ligands can be categorized into two classes, synthetic and natural products.  
Most of known ligands with high affinity belong to the first class.  This class includes 
benzo[a]pyrene, polychlorinated dibenzo-p-TCDDs (PCDDs), polychlorinated 
dibenzofurans (PCDFs), polychlorinated biphenyls (PCBs) and related compounds, such 
as 2,3,7,8 tetrachlorodibenzo-p-TCDD (TCDD) comprising “classical ligands” as termed 
by Denison et Al (65).  As the structures of recently identified ligands are substantially 
different from the classical ligands, these new synthetic AHR can be classified as “non-
classical synthetic ligands” also termed by Denison et al (65).  The overall biological 
activity and the binding affinity of non-classical ligands are not comparable to the 
classical ligands such as TCDD.  However, the identification of these non-typical 
synthetic ligands have broadened the structural spectrum of ligands to a wide diversity, 
suggesting that the chemical structure of ligands should not be restricted to the rigid 
structure based on the observation in classical ligand. 
The classical ligands are the aryl hydrocarbons of coplanar, rigid plural aromatic 
ring structure.  The structure gains more rigidity by the polynuclear aromatic ring 
structures or halogen substituents.  The general ability inducing the activation of AHR 
resulting in the up- regulation of XRE-regulated gene products of these compounds and 
the binding affinity are enormously strong (65).  The non-classical ligands, on the other 
hand, have divergent structures with less rigidity.  These compounds are chemically 
labile, hence, relatively easy to be processed by XMEs (65).  Their interaction with the 
AHR and potency for AHR activation are weak as a whole as compared to the classical 
ligands.   
AHR ligands are easily misunderstood to be air-pollutants or the other 
environmental contaminants, since the classical ligands are usually generated from 
combustion or chemical synthesis.  However, a substantial proportion of the total 
exposure to AHR ligands for humans comes from diet (65).  Thus far, a wide variety of 
dietary AHR ligands have been identified from plants and characterized.  A large 
majority of phytochemicals are antagonists of AHR with weak agonistic activity (65).  
However, the exposure to the dietary ligand of AHR continues throughout the life, hence, 
accumulating the effect of phytochemicals to the body.  Therefore, the total effect of 
phytochemicals for AHR activation should not be overlooked.  
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Figure 2.4 Non-classical ligands of AHR; omeprazole (66), (1S,2R)-(-)-cis-1-Amino-2-
indanol (67) , SKF71739 (68) , 2-(4-Amino-3-methylphenyl)benzothiazole (69) , 5-
Methyl-2-phenylindole (65, 70), YH439 (71), 2-Methylmercaptoaniline (67), ITE;[2-
(10H-indole-30-carbonyl)-thiazole-4-carboxylic acid methyl ester (72), 1,5-Diamino 
naphthalene (73), SRN-P1:109,NH2 (67), 1-Methyl-1-phenylhydrazine (67), VAF347 (74, 
75), Thiabendazole (76,77), M50367 (78, 79) and Guanabenz (80).  
14 
 
 
 
 
Figure 2.5 Naturally occurring ligands and endogenous ligands of AHR; L-tryptophan 
(81), indolo-(3,2-b)-carbazole (82), FICZ; 6-formylindolo-(3,2-b)-carbazole (83), indigo 
(84), indole 3-carbinol (85), 3,3'-diindolylmethane (85), indirubin (84), 6,12-diformyl 
indolo-(3,2-b)-carbazole (82), flavone(86, 87) , flavanone (88, 89), flavan (88, 90), 
isoflavone (91, 92), emodin (93), sulforaphane (94, 95), resveratrol (96, 97), dibenzoyl 
methane (98), diosmin (99), curcumin (100), lipoxin A4 (101), 7-ketocholesterol (102), 
prostaglandin G2 (103), cAMP (104), canthaxanthin (105, 106), bilirubin (107, 108). 
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Interestingly, several precursors are not potent in terms of agonistic activation of 
AHR, whereas simple modifications on structures can cause agonistic activities (65).  
Hence, it is suggested that the structure activity studies on these analogues of ligands and 
precursors will be helpful for the understanding on the structure activity relationship and 
for the rational design of synthetic ligands of AHR.   
A number of studies revealed that while AHR is involved in many biological 
processes, the physiological role of the AHR, however, is not fully understood.  More 
than anything else, endogenous ligands with high affinity have not been identified until 
the present time.  Since the activation of AHR was observed in cultured cell in the 
absence of exogenous ligands, the endogenous ligands of AHR has been expected to be 
present (58).  Thus far, a variety of endogenous ligands have been identified with weak 
agonistic activity compared to TCDD, suggesting the physiological role in cells.  These 
ligands include indoles, arachidonic acid metabolites, carotinoids, cholesterol, and 
prostaglandin G (65).  Taken together, it appears that the AHR plays a certain role in cells 
in the absence of exogenous ligands. 
  
 
2.2.2 Antagonists 
 
 Despite of its usage as a molecular tool and potential therapeutic strategy, a pure 
AHR antagonist has not been developed, a number of flavonoids and their synthetic 
derivatives have been reported to exhibit AHR antagonistic activity.  These include 7,8-
naphthoflavone (α-naphthoflavone; ANF) (109),  3'-methoxyflavone (110), 3'-methoxy-
4'-nitro-flavone (111), 4'-amino-3'-methoxy-flavone (112), 2'-amino-3'-methoxy-flavone 
(PD98059) (89), 4'-methoxyflavone (113) and 3',4'-dimethoxyflavone (112-114).  
Amongst these compounds, the 3‟4‟-dimethoxyflavone (DMF) is widely used as an AHR 
antagonist, since it inhibits AHR activation induced by TCDD in breast cancer cell line 
(113).  However, most of synthetic derivatives exert protein tyrosine kinase inhibitory 
activity and cytotoxicity at a concentration higher than 10 µM as well as partial agonistic 
activity (89, 110, 115).  Recently, CH-223191 was identified as an AHR antagonist by 
screening a diversity-oriented random library (116).  CH-223191 has not been reported to 
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induce AHR activation, implying that this compound may presumably be a pure 
antagonist.  However, it is yet confirmed whether CH-223191 is truly a pure AHR 
antagonist in cells. In the present study, we used the CH-223191 scaffold to generate a 
library of CH-223191analogues and screened for AHR antagonistic activity.  The 
selected compounds were then used to develop PROTACs targeting AHR. 
 
 
Figure 2.6 Antagonists of AHR; 3'-Methoxy-flavone, 3'-Methoxy-4'-nitro-flavone, 4'-
Amino-3'-methoxy-flavone, 2'-Amino-4'-methoxy-flavone, PD98059; 2'-Amino-3'-
methoxy-flavone, 3',4'-Dimethoxy-flavone, 4'-Methoxy-flavone, SP600125, CH223191 
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2.3 PROTAC technology 
 
PROTAC (Proteolysis targeting chimera) is a chimeric small molecule designed 
to induce the proteolysis of targeted protein by the intracellular ubiquitin-proteasome 
system (UPS).  The PROTAC is comprised of a specific E3 ubiquitin-ligase recognition 
motif linked to a ligand that binds to a targeted protein.  PROTAC recruits the targeted 
protein to the specific E3-ligase complex in proximity for multi- and poly- ubiquitination 
and subsequently induces the degradation of targeted protein by the 26S proteasome in an 
ATP-dependant manner (1).  Unlike the conventional small molecules that inhibit protein 
function by direct or indirect interactions with the targeted protein, PROTACs inhibit 
protein function by the elimination of targeted protein rather than by simple inhibition, 
providing an alternative strategy for the modulation of protein function (4). 
 
 
Figure 2.7 Structure of PROTAC 
 
Thus far, several PROTACs have been developed, validating the PROTAC 
approach as a useful research tool.  Target proteins of these PROTACs include estrogen 
receptor α (ER α), methionine amino peptidase 2 (MetAP2), and androgen receptor (AR) 
(1, 5, 117-120).  However, the PROTAC technology has not been widely applied as a 
molecular probe despite its promising potential due to the lack of general design strategy 
and  the limited number of protein-ligand pairs (4).   
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While the ligand for a target protein accounts for the specificity of the target, the 
E3 ligase recognition motif is responsible for ubiquitination.  In the first generation 
PROTACs, a diphosphorylated peptide residue derived from IκB was employed as an E3 
ligase recognition residue (1). 
Despite that the first generation PROTAC successfully induced the degradation of 
targeted protein, its delivery and stability in cells is a major concern due to its 
phosphopeptidyl nature.  The second generation PROTACs used peptide fragments 
derived from HIF-1α (3, 118).  It should be noted that HIF-1α under normoxic conditions 
is rapidly recruited to pVHL complex (E3 ligase complex) for ubiquitination and 
degradation (121, 122).  The second generation PROTAC has been shown to successfully 
induce the degradation of the target protein (3, 118).  The third generation PROTAC is 
equipped with the simplified version of recognition motif of HIF-1α (4).  The HIF-1α 
peptide residue (degron peptide) is a pentapeptide of which the hydroxyproline is in the 
middle and the carboxylic acid is protected with benzyl group from the C-terminal 
proteases attack, whereas the HIF-1α peptide of the second generation PROTAC is an 
octapeptide and its C-terminus is unprotected.  The PROTACs containing the 
pentapeptide are relatively simple to synthesize compared to the former generation 
PROTACs and still capable of inducing the degradation of targets.  Most importantly, 
these PROTACs are cell-permeable.  The next generation PROTAC employing nutlin 
which is known to interact with mdm2, the E3 ligase of p53, has been developed, but its 
activity is, at most, comparable to the activity of PROTACs based on the HIF-1α 
pentapeptide.  Therefore, in the present study, the HIF-1α pentapeptide was employed for 
the synthesis of AHR-targeting PROTAC. 
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2.4 The development of PROTAC as an antagonist of AHR signaling pathway 
 
Considering the unique activity of PROTACs in inducing the degradation of its 
target, it is thought that the PROTAC technology may provide a novel chemical tool in 
dissecting complex signaling pathways.  Thus, it is hypothesized that the PROTAC 
targeting AHR will provide a pure AHR antagonist.  In addition, it is expected that the 
activity of PROTAC will be improved by linking an optimum AHR ligand to the E3 
ligase recognition motif.  Further, screening a small molecule library synthesized in this 
study may provide AHR ligands of the intrinsic antagonistic (or agonistic) activity, which 
may be a useful research tool for the study of AHR and a potent therapeutic agent as well. 
In this study, the PROTAC targeting AHR was first developed using the natural 
product AHR antagonist apigenin.  This provided the proof of concept that exogenous 
ligands can be exploited for the development of PROTAC targeting AHR.  With this in 
mind, the development of PROTACs based on synthetic antagonists has been initiated, 
which aims to develop PROTACs with higher activity and specificity.  
As it is designed to target only the protein which binds to the ligand part of the 
PROTAC, the availability of ligands defines the extent of PROTAC development.  Thus, 
the systemic platform to identify the adequate ligand is desired to improve the 
antagonistic potency.  In order to overcome the limits revealed in previous studies, we 
employed a positional scanning approach to identify AHR ligands that can be used to 
design PROTACs, using the scaffold of CH-223191.  The selected compounds were then 
coupled to the HIF-1α pentapeptide, completing the synthesis of PROTACs that target 
AHR for degradation.   
 
 
 
 
 
 
Copyright © Hyosung Lee 2010 
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CHAPTER 3 PROTAC BASED ON NATURAL PRODUCT 
 
 
3.1 Introduction 
 
 Since the efficacy of PROTAC technology has been demonstrated for a number of 
protein targets, it was hypothesized that PROTAC that targets the AHR selectively 
induces degradation of AHR. Although a number of AHR ligands are available, the use 
of those ligands for the synthesis of PROTAC is limited due to several factors such as 
difficulties of chemical manipulation and the loss of AHR binding affinity caused by 
derivatization.  Recently, Zhang et al. reported that kaempferol and apigenin exhibited 
AHR antagonistic activity in breast cancer cells and liver carcinoma cells, respectively 
(93).  Accordingly, a number of phytochemicals such as apigenin, emodin, kaempferol, 
Genistein, Chrysin and Quercetin have been selected for the test of their activity against 
AHR (Figure 3.1).  Using a luciferase reporter assay, apigenin and kaempferol were 
found to be best antagonists among them (123).  Furthermore, the structure of these 
compounds has an ideal functional group for the attachment of E3 ligase recognition 
motif without the loss of AHR antagonistic activity.   
 
 
Figure 3.1 Phytochemicals interacting with AHR 
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3.2 Apigenin and PROTAC 
 
 Apigenin, which is found in apple, celery, tea, aromatic plants and honey, is 
identified as an AHR antagonist. Previous study revealed that apigenin (1) directly 
interacts with the AHR and inhibits AHR activation (123).  Apigenin has been 
demonstrated to inhibit the proliferation of keratinocytes and prostate cancer cell (124-
126).  In addition, apigenin has shown to be effective for cancer prevention in vitro and in 
vivo (91, 127).  Thus, it was decided to use apigenin in the synthesis of PROTAC that 
targets the AHR. After careful structure-activity-relationship study using acetylated 
apigenin, it was found that three hydroxyl groups in the rings can be derivatized without 
the loss of its activity (Figure 3.2).  
 
 
3.2.1 Optimization of coupling position 
 
 
 
 Figure 3.2 The synthesis of acetylated apigenins. 
 
 
To investigate the role of hydroxyl groups in binding to AHR, the acetylated 
apigenins varying in position and number of acetyl group were prepared and subjected to 
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biological assessment.  Apigenin was deprotonated by excess amount of potassium 
carbonate and treated with acetic anhydride to afford three acetylated apigenins in a one-
pot manner (Figure 3.2).  The resulting derivatives were tested the ability blocking AHR 
activation induced by TCDD.  As shown in Figure 3.3, all of the acetylated apigenin 
derivatives retained the ability suppressing the transcriptional activation mediated by 
AHR, implying that none of these hydroxyl groups are critical for the interaction with 
AHR.   
 
 
  
 
Figure 3.3 The effect of apigenin and acetylated derivatives on the activation of AHR. 
HepG2 cells transfected with human CYP1A1 promoter (HepG2-p450luc) was pre-
treated with either DMSO alone or with the compounds (10
-5 
M to 10
-8 
M).  After 1hr, 
TCDD (1 nM) was added. 4 hr after TCDD treatment the cells were harvested and 
luciferase activities were measured. MNF (3-methoxy-4-nitroflavone, 10 µM) was used 
as a positive control. These assays were performed by a former student, Dinesh Puppala, 
Ph.D., under the direction of Hollie I. Swanson, Ph.D. 
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3.2.2 Synthesis of PROTACs based on apigenin 
 
As the optimization study indicated that none of the three hydroxyl groups are 
important for the interaction with AHR, 4‟-hydroxyl group was chosen for the coupling 
with E3 ubiquitin ligase recognition moiety.  Accordingly, two different PROTACs were 
prepared and evaluated for the ability to induce the degradation of AHR (Figure 3.4).  
The PROTAC containing inactive mutant peptide in which the critical hydroxyproline is 
replaced with alanine was prepared and used as a negative control.  The E3 ubiquitin 
ligase recognition moiety was separately prepared in a conventional method for peptide 
synthesis for the coupling with the linker-attached apigenin (Figure 3.5).  The structures 
of the PROTACs are shown in Figure 3.6 A.   
  
 
Figure 3.4 Synthetic schemes for the preparation of apigenin-based PROTACs.  
a. Methyl-11-bromo undecanoate, K2CO3; b. Benzyl bromide (for compound 4 only); c. 
LiOH; d. 1. HBTU/ HOBt, Diisopropylethylamine, E3 ubiquitin ligase recognition 
peptide (21: H2N-Leu-Ala-Pro
OH
-Tyr-Ile-OBn). 2. TFA.  
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Figure 3.5 Synthetic schemes for the preparation of E3 ligase recognition peptide. 
(A) and inactive mutant peptide, (B) a. HBTU/ HOBt, Diisopropylethylamine; b. 20% 
piperidine in DMF  
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3.2.3 Biological assessment of PROTACs based on apigenin  
 
The results shown in Figure 3.6 B indicated that the PROTACs successfully 
induced the degradation of AHR.  PROTAC1 induced the complete degradation at a 
concentration of 100 µM whereas the effective concentration range of PROTAC2 was 
less than 10 µM, hence, implying that the potency of PROTAC2 would be higher than 
that of PROTAC1. Then, the effect of apigenin-based PROTACs on the expression of 
cytochrome p450 1A1 (CYP1A1) which is regulated by AHR was then investigated.   
The results shown in Figure 3.6 B also indicated that both PROTACs inhibited the 
activation of AHR in terms of the up-regulation of CYP1A1 induced by TCDD.  
However, the CYP1A1 level in the presence of PROTAC1 was observed to be slightly 
higher than that of control whereas PROTAC2 did not induce the increase of CYP1A1 
level, implying that PROTAC1 might be a weak agonist and PROTAC2 would be a more 
useful tool in order to induce the degradation of AHR without activating signaling 
pathway.  
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3.2.4 Confirmation of biological activity of PROTAC2 (4, 128) 
 
To further examine the PROTAC-induced AHR degradation, GFP (green 
fluorescent protein)-fused AHR was over-expressed in HepG2 cells and the cells were 
treated with PROTAC2. The result showed that PROTACs induced degradation of GFP-
fused AHR (Figure 3.7 C).  Then, the role of proteasome in the degradation of the fusion 
protein was investigated by treatment of a natural product proteasome inhibitor 
epoxomicin.  The proteasome inhibitor efficiently blocked the degradation of the fusion 
protein, implying that the PROTAC-induced degradation is proteasome-dependent. 
Since the PROTACs have been demonstrated to induce the degradation of AHR in 
human keratinocytes, HaCaT cells, it was questioned if the PROTACs are capable of 
inducing the degradation of AHR in the other cells.  The result demonstrated that the 
PROTAC2 induced AHR degradation in mouse hepatocyte cells and human hepatocyte, 
HepG2 cells (Figure 3.7 B and C). 
  The PROTAC-induced degradation of AHR was further investigated in mouse 
hepatocyte.  The AHR were demonstrated to be degraded in response to the treatment of 
PROTAC2 in a dose dependent manner (Figure 3.7 A).  In addition, it was observed that 
the AHR activation induced by TCDD was blocked by PROTAC2, whereas the 
PROTAC2 did not induce the increase the CYP1A1 level, implying that PROTAC2 
might be acting as a pure antagonist in the AHR signaling pathway.   
To further examine PROTAC2-induced AHR degradation, enhanced green fluorescent 
protein (eGFP)-fused AHR was over-expressed in the CV-1 cells.  The result showed that 
PROTAC2 efficiently induced degradation of eGFP-fused AHR in the cells (Figure 3.7 
D). The degradation of eGFP–AHR was completely blocked by Epoxomicin, indicating 
that PROTAC2-induced eGFP–AHR degradation is proteasome-dependent. This result 
was verified by cy3-tagged anti-AHR IgG.  
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Figure 3.7 PROTAC2 induces degradation of AHR.  
A) PROTAC-induced degradation of AHR in immortalized mouse hepatocytes.  The cells 
were treated with DMSO (0.1 %), TCDD (1 nM), apigenin (10 M) or PROTAC2 (10, 25, 
50 and 100 M) for 25 hr.  After harvesting, the cell lysates were subjected to western blot 
analysis.  B) and C) PROTAC-induced degradation of AHR in mouse hepatocyte (B) and 
human HepG2 (C).  The cells were treated with DMSO (0.01 %), TCDD (1 nM), 
PROTAC2 (10 M) or epoxomicin (10 M) for 24 hr as indicated. After harvesting, the 
cell lysates were subjected to western blot analysis.  D) PROTAC2 effectively degrades a 
eGFP-fused AHR in CV1 cells. After transfecting with eGFP-fused AHR, the cells were 
treated with DMSO control, a specific proteasome inhibitor epoxomicin alone (10 nM) or 
PROTAC2 (10 M) in the presence or absence of proteasome-specific inhibitor 
epoxomicin (10 nM).  After 16 hr, the cells were visualized by fluorescent microscope. 
The western blot assays were performed by Eun-Young Choi, Ph. D. and a former student, 
Dinesh Puppala, Ph. D. under the direction of Hollie I. Swanson, Ph. D..  The confocal 
data were prepared by Wendy S Katz, Ph. D. 
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3.2.5 Characterization of PROTAC2 
 
The antagonistic activity of PROTAC2 toward AHR prompted the further study 
of the PROTACs. To probe the stage where the signaling is blocked the effect PROTAC 
on the sequential events of each mechanistic steps following AHR ligand binding were 
investigated in.  As PROTAC2-induced decrease of CYP1A1 protein level was shown in 
the presence of TCDD, the effect of PROTAC2 on the upstream stage, the transcription 
level of XRE-regulated gene was investigated.  As a result, it was demonstrated that the 
TCDD-induced increase of mRNA level of CYP1A1 and CYP1B1 were blocked by 
PROTAC2 in dose-dependent manners (Figure 3.8 A).  Next, the earlier stage of the 
signaling pathway, the binding of AHR/ARNT dimer to XRE on DNA as a 
transcriptional factor was investigated.  As a result, the TCDD-induced DNA binding of 
AHR was demonstrated to be inhibited by PROTAC2 (Figure 3.8 B).  These results 
indicate that PROTAC blocked the activation of AHR at earlier stages proceeding 
transcriptional activation.  
As apigenin has been reported to exert the inhibitory activity toward proteasome, 
it was questioned whether or not the PROTAC2 also inhibits the proteasome activity 
(129).  Further, since the studies on the PROTAC2 corroborated that the UPS plays a 
pivotal role in the AHR antagonism, the effect of PROTAC2 on the proteasomal activity 
required further investigation. The kinetic study demonstrated that the PROTAC based on 
apigenin did not inhibit the proteasomal activity whereas apigenin exerted a moderate 
inhibitory activity.  The investigation on the IC50 value of three compounds, PROTAC2, 
apigenin and Epoxomicin revealed that the inhibitory activity of PROTAC2 is 
approximately 30 times and 20000 times weaker than that of apigenin and Epoxomicin, 
actually disapproving the PROTAC2 as an inhibitor of the proteasome. The Numerical 
data were shown in the figure 3.8 D. 
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Figure 3.8 The characterization of PROTAC2.  
A) The NHKs were treated with increasing concentrations of PROTAC2 (0.1 M to 10 
M), harvested at the 16 hr time point and then subjected to RT real time PCR analysis. 
The data are representative of three independent experiments.  B) HepG2 cells were 
cultured with either DMSO (0.01%) or TCDD (1 nM) for 1 hr in the absence (Lanes 1 
and 2) or presence (Lanes 3 and 4) of a 7 hr pretreatment with PROTAC2 (10 M).  The 
cells were harvested, nuclear extracts were prepared and EMSA‟s were performed using 
the 32P labeled DRE as the radiolabeled probe. The experiments were quantified by 
phosphor imager analyses (Image quant software) and are expressed relative to the 
TCDD-treated samples. The data depict averages of three independent experiments + SE 
and were analyzed using ANOVA following by Bonferroni's Multiple Comparison Test.  
* implies significantly different from the TCDD treated sample (p value < 0.001).  C) 
Effect of apigenin and apigenin-PROTAC on proteasomal activity. PROTAC2 (10 M), 
apigenin (5 M), and epoxomicin (10 nM) were combined with the fluorogenic peptide 
substrate and assay buffer in a 96-well plate and assayed as described under Materials 
and Methods for biology. The reactions were allowed to proceed for 90 min, and 
fluorescence data were evaluated in 1-min intervals. Fluorescence was quantified as 
arbitrary units, and progression curves were plotted for each reaction as a function of 
time.  D) The corresponding IC50 values for each treatment are indicated in the table. The 
PCR and EMSA assays were performed by Eun-Young Choi, Ph. D. and a former 
student, Dinesh Puppala, Ph.D. under the direction of Hollie I. Swanson, Ph. D. 
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3.3 Discussion 
 
 In this chapter, it was investigated whether the AHR can be targeted by the 
PROTAC approach.  To test this, the natural product apigenin was used as an AHR 
ligand residue in the design of AHR-targeting PROTAC as a proof of concept experiment. 
Despite the fact that apigenin was a phytochemical identified as an antagonist of AHR, its 
use as an antagonist is limited in the AHR studies due to its partial agonistic activity at 
high concentrations (93).  In addition, apigenin has been shown to display other 
biological activities, such as  activation of the estrogen receptor (130).  
 However, it has been recently found that apigenin (1) directly interacts with the 
AHR and inhibits the ability of the AHR to activate genes (131).  This phytochemical 
which is frequently found in apple, celery, tea, leafy aromatic plants, and honey, is a low 
estrogenic flavonoid phytochemical with anticancer properties (127).  For example, 
apigenin
 
has been shown to strongly inhibit the proliferation of keratinocytes and prostate 
cancer cells (124-126). 
 
More recently, apigenin has been evaluated for its beneficial 
effect on cancer prevention in vitro and in vivo (91, 132, 133).  Taken together, these 
studies support the notion that apigenin may provide a promising avenue for the 
development of an AHR-based chemoprevention drug without serious adverse effect or 
toxicity.  To this end, we envisioned that a PROTAC designed on the relationship 
between apigenin and AHR may provide the proof of principle, exhibiting AHR 
antagonistic activity. 
 The lack of understanding on the roles of hydroxyl groups on apigenin structure 
should be noted.  Even though we tested the effects of acetyl protections of the hydroxyl 
groups, the result does not represent to entire roles of hydroxyl groups.  We briefly 
extracted the idea that acylation on the hydroxyl group will be tolerated for AHR 
antagonistic activity from the data.  However, the exact roles of the hydroxyl groups are 
yet to be elucidated.  Actually, the overall activity of PROTAC1 appeared to be lower 
than PROTAC2 in spite that apigenin is simply coupled to the degron peptide as 
suggested.  Although PROTAC2 fortunately induced a significant decrease in AHR level 
subsequently exhibiting antagonistic activity, we can't rule out the possibility that this 
34 
 
may be due to the additional benzyl moiety on 7-hydroxyl group rather than apigenin 
moiety. 
 As shown above, the apigenin-based PROTAC successfully induced degradation 
of the AHR in a dose-dependent manner as shown above.  Consistent with the Western 
blot results, the transcriptional activation of AHR induced by TCDD was efficiently 
blocked by PROTAC2.  Further, the detailed studies on PROTAC2 in the AHR signaling 
pathway characterized the PROTAC2 as an antagonist of AHR that lacked agonistic 
potency.  In summary, the proof of concept experiment demonstrated that AHR can be 
successfully targeted by the PROTAC approach.  
 The low agonistic activity of ligand head of a PROTAC is desired, since the 
PROTAC based on an agonist is thought to be able to activate the AHR signaling 
pathway.  Furthermore, the lack of toxicity or other adverse effect of ligand head is also 
required in order to reduce the negative influence when this ligand is released from 
PROTAC.  In this context, dietary phytochemicals with low agonistic activity were 
thought to be suitable for the ligand part of PROTAC.  However, one of our major 
concern was specificity and off-target effect.  Since apigenin has also been reported to 
exhibit a wide range of various biological activities including its potency as an agonist in 
AHR signaling cascade (93), it has been suggested that it may target multiple proteins.  
Therefore, the possibility that the apigenin-based PROTAC may also suffer from off-
target hits led to the development of AHR ligands that may exhibit higher specificity. 
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3.4 Materials and Methods 
 
Material 
PROTAC1, PROTAC2, and PROTAC3 were synthesized as described below. 
TCDD was a generous gift from Dr. Stephen H. Safe (Texas A&M University, College 
Station, TX). [
3
H]TCDD was obtained from ChemSyn Laboratories (Lenexa, KS).  
Unless otherwise mentioned, all other chemicals were purchased from Sigma-Aldrich (St. 
Louis, MO). 
 
Cell Culture 
Neonatal primary human keratinocytes (NHKs) were purchased from Cascade 
Biologics (Portland, OR).  The cells were grown in Epilife medium with EDGS (Cascade 
Biologics) at 37°C and 5% CO2.  Murine (Hepa1c1c7) and human hepatoma (HepG2) 
cells were maintained in Dulbecco‟s modified Eagle‟s media with glucose and glutamine 
(Mediatech, Herndon, VA) supplemented with 10% fetal bovine serum (Invitrogen, 
Carlsbad, CA) at 37°C and 5% CO2. 
 
Luciferase assays 
The HepG2-Luc cells were cultured in 96-well assay plates and
 
pretreated with 
either DMSO alone or with the compounds at the
 
indicated concentrations for 1 h. 
Subsequently, the cells were
 
treated with TCDD (1 nM) for 4 h. The cells were then 
harvested
 
and the CYP1A1 promoter activity was determined as a measure
 
of luciferin 
generated using the Luciferase Assay System kit
 
from Promega according to the 
manufacturer's protocol using
 
TR 717 Microplate Luminometer from Applied Biosystem 
(Foster
 
City, CA).  
 
Electrophoretic Mobility Shift Assays 
The impact of PROTAC2 on the AHR/ARNT DNA binding complex formed in 
cultured cells was determined by pretreating HepG2 cells with PROTAC2 for 7 h before 
the administration of either DMSO (0.1 %) or TCDD (1 nM).  After an 1 h incubation, 
the cells were harvested, and nuclear extracts were prepared using the Nucbuster protein 
36 
 
extraction kit (Novagen, Madison, WI).  Aliquots of the extracts (12 µg) were incubated 
with salmon sperm DNA (1 µg) and KCl (0.1 M final concentration) at room temperature 
for 15 min.  The samples were then incubated for an additional 15 min at room 
temperature with the radiolabeled (32P) consensus DRE sequences, 
(forward)TCGAGCTGGGGGCATTGCGTGACATTAC and (reverse) TCGA 
GGTATGTCACGCAATGCCCCCAGC, as described previously (131).  After a 15-min 
incubation, the samples were separated using 4 % polyacrylamide nondenaturing 
electrophoretic gel and 0.5 × Tris borate-EDTA (45 mM Tris base, 45 mM boric acid, 
and 1 mM EDTA, pH 8.0) as the running buffer. 
 
Western Blot Analyses 
NHKs were seeded into six-well plates. Once they reached approximately 70% 
confluence, they were treated with the indicated chemicals for varying time periods as 
described in the figure legends. The cells were harvested, and the total cellular extracts 
were prepared using radioimmunoprecipitation assay buffer (50 mM Tris, pH 7.5, 150 
mM NaCl, 1 % Nonidet P-40, and 0.5 % sodium deoxycholate). The protein 
concentrations were estimated using BCA analysis (Pierce, Rockford, IL). Aliquots of the 
cellular extracts (approximately 100 µg) were separated using SDS-polyacrylamide gel 
electrophoresis, and the proteins were transferred to nitrocellulose membranes. After a 
brief incubation in blocking buffer, the blots were probed using antibodies that 
recognized AHR (Abcam, Cambridge, MA), CYP1A1 (Santa Cruz Biotechnology, Santa 
Cruz, CA), and β-actin (Sigma-Aldrich). 
 
Immunocytochemistry 
CV-1 cells (monkey kidney cells) were plated in 6 well plates with coverslips. At 
50 ~ 70 % confluency, the cells were transiently transfected with AHR-GFP plasmid 
using Lipofectamine 2000. After 32 hours, cells were treated with either DMSO (0.01 
%), Epoxomicin (10 nM) or PROTACs2 (10 µM) as described in the figure legends and 
the cells were incubated for an additional 16 hours.  The cells were then washed twice 
with 1X PBS and were then fixed for 15 minutes in fresh formaldehyde.  After washing 
with PBS, the cells were incubated overnight with blocking buffer (PBS Teleostin gelatin 
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0.1% Triton X-100).  On the next day, the cells were washed with 1 × PBS, incubated 
with normal blocking serum (1 × PBS and secondary antibody serum) for 20 minutes and 
finally, incubated with the primary GFP antibody (Abcam) for 60 minutes.  The cells 
were then washed twice with 1 × PBS and were then incubated with the secondary CY3 
antibody (Cat. No 111-166-047 from Jackson Immunoresearch labs) for 60 minutes. The 
coverslips were then mounted on slides using mounting media containing DAPI stain 
(Prolong Gold antifade reagent Cat no. P 36931 from Invitrogen) and visualized using a 
40 × confocal microscope (Leica TCS SP5 inverted microscope) 
 
RT Real-Time PCR 
The cells were harvested at the time points described in the figure legends, and 
the RNA was extracted using TRIzol reagent (Invitrogen).  For RT real-time PCR, the 
cDNA was prepared using the manufacturer‟s protocol for Omniscript RT kit (Qiagen, 
Valencia, CA) and random primers (Invitrogen).  The cDNA was then analyzed using 
Brilliant SYBR Green QPCR Master Mix and Human QPCR Reference RNA 
(Stratagene).  Oligonucleotide primers were synthesized by Integrated DNA 
Technologies, Inc. (Coralville, IA) and were specifically designed using Vector NTI 9.0.0 
(InforMax; Invitrogen Life Science Software, Frederick, MD) to amplify regions 
spanning exon junctions.  For CYP1A1, the primer sequences were the following: 
forward, 5‟-CAAAACCTTTGAGAAGGGCCACATC-3‟; and reverse, 5‟-GACAGCTG 
GACATTGGCGTTCTC-3‟. For CYP1B1, the primer sequences were the following: 
forward, 5‟-GCTGCTCCTCCTCTTCACCAGGTA-3‟; and reverse, 5‟-GCTGGTCACC 
CATACAAGGCAGAC-3‟. 
 
Proteasome Inhibition Kinetics Assays 
Apigenin, PROTAC2, or epoxomicin was mixed with a fluorogenic peptide 
substrate and assay buffer (20 mM Tris, pH 8.0, 0.5 mM EDTA, and 0.035 % SDS) in a 
96-well plate.  The chymotrypsin-like activity was assayed using the fluorogenic peptide 
substrates Suc-Leu-Leu-Val- Tyr-AMC (Sigma-Aldrich).  Hydrolysis was initiated by the 
addition of human erythrocyte 20S proteasome (Biomol International, Plymouth Meeting, 
PA), and the reaction was monitored by fluorescence (360 nm excitation/460 nm 
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detection) using a Microplate Fluorescence Reader (FL600; Bio-Tek Instruments, Inc., 
Winooski, VT) using the software KC4 v.2.5 (Bio-Tek Instruments).  The reactions were 
allowed to proceed for 90 min, and fluorescence was detected every 1 min.  Fluorescence 
was quantified as arbitrary units, and progression curves were plotted for each reaction as 
a function of time.  The range of concentrations tested was chosen such that several half-
lives could be observed during the course of the analyses. 
 
Statistical Analysis 
The data were analyzed using analysis of variance (ANOVA) with Bonferroni‟s 
multiple comparison test as mentioned in the figure legends. 
 
 
Synthesis of acetylated apigenin derivatives 
 
To a solution of apigenin (20.0 mg, 0.0740 mmol) in DMF (1 ml) added acetic 
anhydride (34.0 mg, 0.333 mmol) and N,N-dimethylaminopyridine (0.5 mg, 0.0041 
mmol). After stirring for 1 hour, the resulting mixture was concentrated under vacuum 
and subjected to flash column chromatography (CH2Cl2: MeOH = 99:1) yielding three 
acetylated apigenins as yellowish solids.  
 
4‟,7-diacetyl-apigenin:  1H NMR: δ = 7.92 (d, J = 7.5 Hz, 2H), 7.29 (d, J = 7.5 Hz, 2H), 
6.84 (s, 1H), 6.65 (s, 1H), 6.59 (s, 1H), 2.37 (s, 6H) ppm.  Mass calcd. for [M] 354.07, 
found (ES) [M] 354. 
 
4‟,5,7-triacetyl-apigenin:  1H NMR: δ = 7.87 (d, J = 7.5 Hz, 2H), 7.39 (s, 1H), 7.24 (d, J = 
7.5 Hz, 2H), 6.83 (s, 1H), 6.61 (s, 1H), 2.44 (s, 3H), 2.36 (s, 6H) ppm.  Mass calcd. for 
[M] 396.08, found (ES) [M] 396. 
 
4‟,5-diacetyl-apigenin:  1H NMR: δ = 7.90 (d, J = 7.5 Hz, 2H), 7.23 (d, J = 7.5 Hz, 2H), 
6.83 (s, 1H), 6.58 (s, 2H), 2.42 (s, 3H), 2.37 (s, 3H) ppm. Mass calcd. for [M] 354.07, 
found (ES) [M] 354. 
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Synthesis of PROTACs 
 
Synthesis of 6  
To a solution of apigenin (100 mg, 0.3695 mmol) in DMF (2 ml) was added 
K2CO3 (70 mg, 0.2586 mmol) and methyl-11-Bromoundecanoate (103.2 mg, 0.3695 
mmol).  After stirring at room temperature for 15 h, the resulting mixture was 
concentrated under vacuum and subjected to flash column chromatography 
(CH2Cl2/MeOH, 95:5) yielding 6 (86.2 mg, 50 %) as a yellowish solid.   
 
1
H NMR: δ = 7.83 (d, J = 8.5 Hz, 2H, 3‟-H, 5‟-H), 7.08 (d, J = 8.5 Hz, 2H, 2‟-H, 6‟-H), 
6.57 (s, 1H, 3-H), 6.46 (s, 1H, 6-H), 6.34 (s, 1H, 8-H), 4.02 (t, J = 6.1 Hz, 2H, O-CH2-), 
3.67 (s, 3H, O-CH3),  2.31 (t, J = 7.3 Hz, 2H, -CH2-CO-), 1.81 (m, 2H, -O-CH2-CH2), 
1.63 (m, 2H, -CH2-CH2-CO-), 1.31 (s, 12H, -C6H12-) ppm. 
 
 
Synthesis of 7  
Compound 6 (25 mg, 0.0534 mmol) in DMF (1 ml) was treated with benzyl 
bromide (33 mg, 0.2134 mmol) and K2CO3 (26 mg, 0.1880 mmol) to produce 7 (25 mg, 
84 %) at C7-OH position as a major product.  
 
1
H NMR: δ = 7.83 (d, J = 8.5 Hz, 2H, 3‟-H, 5‟-H), 7.35 (m, 5H, -Ph),  7.08 (d, J = 8.5 
Hz, 2H, 2‟-H, 6‟-H), 6.57 (s, 1H, 3-H), 6.46 (s, 1H, 6-H), 6.34 (s, 1H, 8-H), 4.02 (t, J = 
6.1 Hz, 2H, O-CH2-), 3.67 (s, 3H, O-CH3),  2.31 (t, J = 7.3 Hz, 2H, -CH2-CO-), 1.81 (m, 
2H, -O-CH2-CH2), 1.63 (m, 2H, -CH2-CH2-CO-), 1.31 (s, 12H, -C6H12-) ppm. 
 
 
Synthesis of 8  
To a solution of the 6 (25.0 mg, 0.0534 mmol) in THF/H2O, 3:1(1 ml) was added 
LiOH (6.4 mg, 0.2668 mmol). After stirring at room temperature for 15 h, the resulting 
mixture was poured into H2O with cold 1N HCl and extracted with CH2Cl2.  The organic 
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layers were combined, washed with brine, dried over Na2SO4, filtered, concentrated and 
dried under vacuum to yield the free acid of 8 (19.0 mg, 78 %).    
 
1
H NMR: δ = 7.83 (d, J = 8.5 Hz, 2H, 3‟-H, 5‟-H), 7.08 (d, J = 8.5 Hz, 2H, 2‟-H, 6‟-H), 
6.57 (s, 1H, 3-H), 6.46 (s, 1H, 6-H), 6.34 (s, 1H, 8-H), 4.02 (t, J = 6.1 Hz, 2H, O-CH2-), 
2.31 (t, J = 7.3 Hz, 2H, -CH2-CO-), 1.81 (m, 2H, -O-CH2-CH2), 1.63 (m, 2H, -CH2-CH2-
CO-), 1.31 (s, 12H, -C6H12-) ppm. 
 
 
Synthesis of 9  
To a solution of 7 (25.0 mg, 0.0447 mmol) in THF/H2O, 3:1(1 ml) was added 
LiOH (5.4 mg, 0.2237 mmol). After stirring at room temperature for 15 h, the resulting 
mixture was poured into H2O with cold 1N HCl and extracted with CH2Cl2. The organic 
layers were combined, washed with brine, dried over Na2SO4, filtered, concentrated and 
dried under vacuum to yield the free acid 9 (20.0 mg, 81 %).    
 
1
H NMR: δ = 7.83 (d, J = 8.5 Hz, 2H, 3‟-H, 5‟-H), 7.35 (m, 5H, -Ph), 7.08 (d, J = 8.5 Hz, 
2H, 2‟-H, 6‟-H), 6.57 (s, 1H, 3-H), 6.46 (s, 1H, 6-H), 6.34 (s, 1H, 8-H), 4.02 (t, J = 6.1 
Hz, 2H, O-CH2-), 2.31 (t, J = 7.3 Hz, 2H, -CH2-CO-), 1.81 (m, 2H, -O-CH2-CH2), 1.63 
(m, 2H, -CH2-CH2-CO-), 1.31 (s, 12H, -C6H12-) ppm. 
 
 
Synthesis of 10  
To a solution of the resulting free acid 7 (10 mg, 0.0220 mmol) in DMF (1 ml) 
was added HBTU (10.0 mg, 0.0264 mmol), HOBt (4.0 mg, 0.0264 mmol), 
diisopropylethylamine (14.2 mg, 0.1100 mmol) and E3 ubiquitin ligase recognition 
peptide (H2N-Leu-Ala-Pro
OH
-Tyr
t-butyl
-Ile-OBn ; 16.3 mg, 0.0221 mmol). After stirring at 
room temperature for 2 h, the resulting mixture was concentrated under vacuum and 
subjected to flash column chromatography (CH2Cl2/MeOH, 9:1) to yield the fully 
assembled product (10.1 mg, 39 %) as a yellowish solid.   
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1
H NMR: δ = 7.83 (d, J = 8.5 Hz, 2H, 3‟-H, 5‟-H), 7.35 (m, 5H, -Ph), 7.08 (d, J = 8.5 Hz, 
4H, 2‟-H, 6‟-H, 2-HTyr, 6-HTyr), 6.87 (d, J = 8.5 Hz, 2H, 3-HTyr, 5-HTyr), 6.59 (s, 1H, 3-
H), 6.48 (s, 1H, 6-H), 6.36 (s, 1H, 8-H), 5.13 (s, 2H, -O-CH2-Ar), 4.42-4.63 (m, 5H, 
H
α
Leu, H
α
Ala, H
α
Pro
OH
, H
α
Tyr, H
α
Ile), 4.02 (t, J = 6.1 Hz, 2H, -CH2-CO-), 2.84-3.95 (m, 5H, 
H
β
Pro
OH
, H
γ
Pro
OH
, H
δ
Pro
OH
), 3.09 (m, 1H, H
β
Tyr), 2.89 (m, 1H, H
β
Tyr), 2.31(t, J = 7.3 Hz, 
2H, -O-CH2-), 1.93 (m, 2H, H
β
Leu), 1.80 (m, 2H, -CH2-CH2-CO-), 1.63 (m, 2H, -O-CH2-
CH2), 1.55 (m, 2H, H
β
Ile, H
γ
Leu), 1.45 (m, 1H, -CH
γ
2- Ile), 1.31 (s, 12H, -C6H12-), 1.28 (s, 
9H, O-tbutyl), 1.25 (s, 3H, H
β
Ala), 1.17 (m, 1H, -CH
γ
2- Ile), 0.83-1.00 (m, 12H, -CH
γ
3 Ile, 
H
δ
Ile, H
δ
Leu ) ppm.  
 
 
To a solution of the fully assembled product (10.1 mg, 0.0086 mmol) in CH2Cl2 
(0.5 ml) was added trifluoroacetic acid (100 µl, 0.87 mmol) at room temperature for 15 
min to deprotect t-butyl residue of tyrosine within the fully assembled compound. 
Subsequently, the concentrated mixture was dried under high vacuum to remove 
trifluoroacetic acid. The resulting crude product was subjected to flash column 
chromatography (CH2Cl2/MeOH, 9:1) to yield 10 (9.1 mg, 90 %) as a yellowish solid.   
 
1
H NMR: δ = 7.83 (d, J = 8.5 Hz, 2H, 3‟-H, 5‟-H), 7.35 (m, 5H, -Ph), 7.08 (d, J = 8.5 Hz, 
4H, 2‟-H, 6‟-H, 2-HTyr, 6-HTyr), 6.87 (d, J = 8.5 Hz, 2H, 3-HTyr, 5-HTyr), 6.59 (s, 1H, 3-
H), 6.48 (s, 1H, 6-H), 6.36 (s, 1H, 8-H), 5.13 (s, 2H, -O-CH2-Ar), 4.42-4.63 (m, 5H, 
H
α
Leu, H
α
Ala, H
α
Pro
OH
, H
α
Tyr, H
α
Ile), 4.02 (t, J = 6.1 Hz, 2H, -CH2-CO-), 2.84-3.95 (m, 5H, 
H
β
Pro
OH
, H
γ
Pro
OH
, H
δ
Pro
OH
), 3.09 (m, 1H, H
β
Tyr), 2.89 (m, 1H, H
β
Tyr), 2.31(t, J = 7.3 Hz, 
2H, -O-CH2-), 1.93 (m, 2H, H
β
Leu), 1.80 (m, 2H, -CH2-CH2-CO-), 1.63 (m, 2H, -O-CH2-
CH2), 1.55 (m, 2H, H
β
Ile, H
γ
Leu), 1.45 (m, 1H, -CH
γ
2- Ile), 1.31 (s, 12H, -C6H12-), 1.25 (s, 
3H, H
β
Ala), 1.17 (m, 1H, -CH
γ
2- Ile), 0.83-1.00 (m, 12H, -CH
γ
3 Ile, H
δ
Ile, H
δ
Leu ) ppm.  MS 
(MALDI): m/z = 1118, calcd. for C23H42N2O8·Na: m/z = 1117.56. 
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Synthesis of 11 
To a solution of the resulting free acid 9 (10 mg, 0.0184 mmol) in DMF (1 ml) 
was added HBTU (10.4 mg, 0.0275 mmol), HOBt (4.2 mg, 0.0275 mmol), 
Diisopropylethylamine (14.2 mg, 0.1101 mmol) and E3 ubiquitin ligase recognition 
peptide (H2N-Leu-Ala-Pro
OH
-Tyr
t-butyl
-Ile-OBn ; 16.3 mg, 0.022 mmol). After stirring at 
room temperature for 2 h, the resulting mixture was concentrated under vacuum and 
subjected to flash column chromatography (CH2Cl2/MeOH, 9:1) to yield the fully 
assembled product (11.0 mg, 48 %) as a yellowish solid.   
 
1
H NMR: δ = 7.83 (d, J = 8.5 Hz, 2H, 3‟-H, 5‟-H), 7.35 (m, 10H, -Ph), 7.08 (d, J = 8.5 
Hz, 4H, 2‟-H, 6‟-H, 2-HTyr, 6-HTyr), 6.87 (d, J = 8.5 Hz, 2H, 3-HTyr, 5-HTyr), 6.57 (s, 1H, 
3-H), 6.46 (s, 1H, 6-H), 6.34 (s, 1H, 8-H), 5.13 (s, 4H, -O-CH2-Ar), 4.42-4.63 (m, 5H, 
H
α
Leu, H
α
Ala, H
α
Pro
OH
, H
α
Tyr, H
α
Ile), 4.02 (t, J = 6.1 Hz, 2H, -CH2-CO-), 2.84-3.95 (m, 5H, 
H
β
Pro
OH
, H
γ
Pro
OH
, H
δ
Pro
OH
), 3.09 (m, 1H, H
β
Tyr), 2.89 (m, 1H, H
β
Tyr), 2.31(t, J = 7.3 Hz, 
2H, -O-CH2-), 1.93 (m, 2H, H
β
Leu), 1.80 (m, 2H, -CH2-CH2-CO-), 1.63 (m, 2H, -O-CH2-
CH2), 1.55 (m, 2H, H
β
Ile, H
γ
Leu), 1.45 (m, 1H, -CH
γ
2- Ile), 1.31 (s, 12H, -C6H12-), 1.28 (s, 
9H, O-tbutyl), 1.25 (s, 3H, H
β
Ala), 1.17 (m, 1H, -CH
γ
2- Ile), 0.83-1.00 (m, 12H, -CH
γ
3 Ile, 
H
δ
Ile, H
δ
Leu ) ppm. 
 
 
To a solution of the fully assembled product (11.0 mg, 0.0087 mmol) in CH2Cl2 
(0.5 ml) was added trifluoroacetic acid (100 µl, 0.87 mmol) at room temperature for 15 
min to deprotect t-butyl residue of tyrosine within the fully assembled compound. 
Subsequently, the concentrated mixture was dried under high vacuum to remove 
trifluoroacetic acid. The resulting crude product was subjected to flash column 
chromatography (CH2Cl2/MeOH, 9:1) to yield 11 (11.0 mg, 99 %) as a yellowish solid.   
 
1
H NMR: δ = 7.83 (d, J = 8.5 Hz, 2H, 3‟-H, 5‟-H), 7.35 (m, 10H, -Ph), 7.08 (d, J = 8.5 
Hz, 4H, 2‟-H, 6‟-H, 2-HTyr, 6-HTyr), 6.87 (d, J = 8.5 Hz, 2H, 3-HTyr, 5-HTyr), 6.57 (s, 1H, 
3-H), 6.46 (s, 1H, 6-H), 6.34 (s, 1H, 8-H), 5.13 (s, 4H, -O-CH2-Ar), 4.42-4.63 (m, 5H, 
H
α
Leu, H
α
Ala, H
α
Pro
OH
, H
α
Tyr, H
α
Ile), 4.02 (t, J = 6.1 Hz, 2H, -CH2-CO-), 2.84-3.95 (m, 5H, 
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H
β
Pro
OH
, H
γ
Pro
OH
, H
δ
Pro
OH
), 3.09 (m, 1H, H
β
Tyr), 2.89 (m, 1H, H
β
Tyr), 2.31(t, J = 7.3 Hz, 
2H, -O-CH2-), 1.93 (m, 2H, H
β
Leu), 1.80 (m, 2H, -CH2-CH2-CO-), 1.63 (m, 2H, -O-CH2-
CH2), 1.55 (m, 2H, H
β
Ile, H
γ
Leu), 1.45 (m, 1H, -CH
γ
2- Ile), 1.31 (s, 12H, -C6H12-), 1.25 (s, 
3H, H
β
Ala), 1.17 (m, 1H, -CH
γ
2- Ile), 0.83-1.00 (m, 12H, -CH
γ
3 Ile, H
δ
Ile, H
δ
Leu ) ppm.  MS 
(MALDI): m/z = 1231, calcd. for C23H42N2O8·Na: m/z = 1230.60. 
 
 
Synthesis of 12 
To a solution of the resulting free acid 9 (10.0 mg, 0.0184 mmol) in DMF (1 ml) 
was added HBTU (10.4 mg, 0.0275 mmol), HOBt (4.2 mg, 0.0275 mmol), 
Diisopropylethylamine(14.2mg, 0.1101mmol) and E3 ubiquitin ligase recognition peptide 
(H2N-Leu-Ala-Pro
OH
-Tyr
t-butyl
-Ile-OBn ; 15.3 mg, 0.0220 mmol). After stirring at room 
temperature for 2 h, the resulting mixture was concentrated under vacuum and subjected 
to flash column chromatography (CH2Cl2/MeOH, 9:1) to yield the fully assembled 
product (11.0 mg, 49 %) as a yellowish solid. 
 
1
H NMR: δ = 7.83 (d, J = 8.5 Hz, 2H, 3‟-H, 5‟-H), 7.35 (m, 5H, -Ph), 7.08 (d, J = 8.5 Hz, 
4H, 2‟-H, 6‟-H, 2-HTyr, 6-HTyr), 6.87 (d, J = 8.5 Hz, 2H, 3-HTyr, 5-HTyr), 6.59 (s, 1H, 3-
H), 6.48 (s, 1H, 6-H), 6.36 (s, 1H, 8-H), 5.13 (s, 2H, -O-CH2-Ar), 4.42-4.63 (m, 5H, 
H
α
Leu, 2H
α
Ala,  H
α
Tyr, H
α
Ile), 4.02 (t, J = 6.1 Hz, 2H, -CH2-CO-), 3.09 (m, 1H, H
β
Tyr), 2.89 
(m, 1H, H
β
Tyr), 2.31(t, J = 7.3 Hz, 2H, -O-CH2-), 1.93 (m, 2H, H
β
Leu), 1.80 (m, 2H, -CH2-
CH2-CO-), 1.63 (m, 2H, -O-CH2-CH2), 1.55 (m, 2H, H
β
Ile, H
γ
Leu), 1.45 (m, 1H, -CH
γ
2- Ile), 
1.31 (s, 12H, -C6H12-), 1.28 (s, 9H, O-tbutyl), 1.25 (s, 6H, H
β
Ala), 1.17 (m, 1H, -CH
γ
2- Ile), 
0.83-1.00 (m, 12H, -CH
γ
3 Ile, H
δ
Ile, H
δ
Leu ) ppm. 
 
To a solution of the fully assembled product (11.0 mg, 0.0090 mmol) in CH2Cl2 
(0.5 ml) was added trifluoroacetic acid (100 µl, 0.87 mmol) at room temperature for 15 
min to deprotect t-butyl residue of tyrosine within the fully assembled compound. 
Subsequently, the concentrated mixture was dried under high vacuum to remove 
trifluoroacetic acid. The resulting crude product was subjected to flash column 
chromatography (CH2Cl2/MeOH, 9:1) to yield 12 (10.4 mg, 99 %) as a yellowish solid.   
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1
H NMR: δ = 7.83 (d, J = 8.5 Hz, 2H, 3‟-H, 5‟-H), 7.35 (m, 5H, -Ph), 7.08 (d, J = 8.5 Hz, 
4H, 2‟-H, 6‟-H, 2-HTyr, 6-HTyr), 6.87 (d, J = 8.5 Hz, 2H, 3-HTyr, 5-HTyr), 6.59 (s, 1H, 3-
H), 6.48 (s, 1H, 6-H), 6.36 (s, 1H, 8-H), 5.13 (s, 2H, -O-CH2-Ar), 4.42-4.63 (m, 5H, 
H
α
Leu, 2H
α
Ala,  H
α
Tyr, H
α
Ile), 4.02 (t, J = 6.1 Hz, 2H, -CH2-CO-), 3.09 (m, 1H, H
β
Tyr), 2.89 
(m, 1H, H
β
Tyr), 2.31(t, J = 7.3 Hz, 2H, -O-CH2-), 1.93 (m, 2H, H
β
Leu), 1.80 (m, 2H, -CH2-
CH2-CO-), 1.63 (m, 2H, -O-CH2-CH2), 1.55 (m, 2H, H
β
Ile, H
γ
Leu), 1.45 (m, 1H, -CH
γ
2- Ile), 
1.31 (s, 12H, -C6H12-), 1.25 (s, 6H, H
β
Ala), 1.17 (m, 1H, -CH
γ
2- Ile), 0.83-1.00 (m, 12H, -
CH
γ
3 Ile, H
δ
Ile, H
δ
Leu ) ppm.  MS (MALDI): m/z = 1169, calcd. for C23H42N2O8·Na: m/z = 
1168.60. 
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CHAPTER 4 IDENTIFICATION OF NOVEL AHR LIGANDS 
 
 
4.1 Introduction 
 
 Thus far, a large number of synthetic or naturally occurring small molecules of 
diverse structures were shown to interact with AHR.  Several compounds such as, 3'-
methoxy-4'-nitroflavone (MNF) and anthraquinones exhibited antagonistic activity and 
have been used to validate the AHR as a therapeutic target for chemoprevention (112, 
134).    Despite the promising activities of these compounds, their use as molecular 
probes is limited due to the lack of specificity and/or the partial potency as an agonist. 
 Recently, Kim and colleagues have reported a novel synthetic antagonist of AHR, 
1-methyl-1H-pyrazole-5-carboxylic acid N-[2-methyl-4-[(2-methylphenyl)diazenyl]-
phenyl]-amide (26) (116).  They screened a large random library of synthetic molecules 
for AHR antagonistic activity (116).  Since the concept of positional scanning of a given 
scaffold has been well-known in identifying the optimal compounds in the development 
of peptide-based ligands, it was thought to be plausible to apply this approach to non-
peptide small molecules to identify optimum compounds.  With this in mind, we 
identified a number of AHR ligands by positional scanning using 1-methyl 1H-pyrazole-
5-carboxylic acid  N-[2-methyl-4-[(2-methylphenyl)diazenyl]-phenyl]-amide as a 
scaffold.  
 Each aromatic ring system of the scaffold was modified stepwise with various 
structures affording a small chemical library.  The resulting library was then screened for 
the ability to block the activation of AHR induced by TCDD using a luciferase reporter 
assay.  N-[2-Methyl-4-[(2-methylphenyl)diazenyl]phenyl]-2-furan carboxamide (31) and 
N-[2-methyl-4-[(2-methylphenyl)diazenyl]phenyl]-2-pyridine carboxamide (36) were 
identified as antagonists and N-[2-methyl-4-[(2-ethylphenyl)diazenyl]phenyl]-2-pyridine 
carboxamide (47) was identified as an agonist.  Interestingly, a diphenyldiazene structure, 
2-methyl-4-[(2-methylphenyl)diazenyl]-aniline (60), exerted antagonistic activity 
whereas the rest of the bipheyls did not show the antagonistic activity.  The detailed 
structure-activity relationship studies revealed that three aromatic rings are critical for the 
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AHR antagonistic activity. The modification on middle ring structure did not change 
parent compound‟s activity, suggesting that the middle ring can be modified to attach 
affinity reagents or prepare PROTACs.   
 
 
4.2 The construction of privileged library 
 
Three aromatic rings of the parent compound are linked through diazenyl- and 
amide linkages (Figure 4.1).  Since the condensation methods for both linkages are well 
established, three synthons were generated:  2-methylphenyl diazenylnium, 2-
methylphenylamino, and 1-methyl-1H-pyrazole-5-carbonyl fragments.  The fragments 
were then converted into the corresponding synthetic equivalents, 2-methylphenyl 
diazenylnium chloride, 2-methyl phenyl amine (o-toluidine), and 1-methyl-1H-pyrazole-
5-carboxylic acid, respectively.  Using modified Wang‟s (135) and Azumaya‟s method 
(136), diazenyl coupling and anilide condensation were sequentially carried out.  Using 
similar strategies, compounds with various structures were synthesized (Figure 4.1). 
 
Figure 4.1 The structure of N-[2-methyl-4-[(2-methylphenyl)diazenyl]-phenyl]-1-Methyl-
1H-pyrdiazenylle-5-carboxamide and the synthetic approach for combinatorial chemistry. 
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4.2.1 C Ring optimization 
 
The positional scanning strategy started with the C ring , while  the structure of A- 
and B- rings was unchanged.  The 1-methyl-1H-pyrazole of the parent compound was 
substituted with various residues: 1) 5-membered or 2) 6-membered aromatic rings 
varying in composition and position, 3) fully saturated cyclic hydrocarbons, 4) 
multinuclear aromatic rings and 5) bulky hydrocarbon (Figure 4.2).   
 Among 17 analogues prepared in these studies, compound 36 and 31 were 
comparable to the parent compound inhibiting AHR action. Interestingly, the compounds 
with fully saturated cyclic hydrocarbons (32, 33) did not inhibit AHR activity.  The 
analogues containing N-methyl indole (35) or pyrene (42) structure exhibited agonistic 
activity whereas multi-ring structures, such as indole (34), naphthalene (38) or anthracene 
(41), did not show any agonistic activity (Figure 4.3). 
The compound containing indole (34) moiety showed weak antagonistic activity 
whereas the analogue containing N-methyl indole (35) exhibited weak agonistic activity 
toward AHR, implying that the methyl group on this structure may influence the action of 
AHR.  The contribution of a methyl group on the activity of was also observed in 
different ring systems such as pyrrole (27, 28) and naphthalene (38, 39), although the 
differences were not as significant as indole ring system.  However, the contribution of 
methyl group was not observed in phenyl and tolyl pairing systems (29, 30).  Differences 
in the activities of analogues containing bulky hydrocarbon, noradamantane (43) or bent 
aromatic ring, acenaphthene (40) were insignificant (Figure 4.3). 
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Figure 4.2 Synthetic scheme and the resulting library of C ring substituted analogues of 
2-methyl-4-[(2-methylphenyl)diazenyl]phenyl carboxamides. 
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4.2.2 A ring optimization 
  
Based on the result of C ring optimization, 2-picolinic group was selected for 
optimum C ring.  Next, A ring was fine-tuned, attaching a methyl group at different 
positions of A ring.  To investigate the impact of these changes, 3-methylphenyl and 4-
methylphenyl groups were substituted with 2-methylphenyl of the parent group and 
tested the effects of these substitution using an AHR reporter assay (Figure 4.4).  
  
 
 
Figure 4.4 Synthetic scheme and the resulting library of C ring substituted analogues of 
2-methyl-4-[(methylphenyl)diazenyl]phenyl picolinic carboxamides 
 
 
In addition, 2-methylphenyl group was substituted with 1) benzene 2) 
halobenzene, 3) short branched phenyl structure 4) long branched structure and 5) large 
aromatic ring structure (Figure 4.4).  The resulting compounds were evaluated for their 
ability to block AHR activation induced by TCDD.  The location of methyl in the A ring 
caused significant changes in biological activity. For example, the antagonistic activity of 
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compound 44 was much lower than that of 36 (Figure 4.3).  Further, the compound 45 
did not show significant antagonistic activity even at the highest concentration, implying 
that the para substituent on the ring would interfere with the interaction between the ring 
and AHR.  The removal of ortho- methyl (46) caused the loss of antagonistic activity 
displaying similar activities with 44 and the activity was restored by 2, 3-benzo 
substitution (51).  Interestingly, when methyl group is substituted with 2-ethyl group, it 
displayed both agonistic and antagonistic activity.  However, the replacement the methyl 
with 2-methyloxy group (50) completely eliminated both activities.  In summary, small 
substituents on ortho position appears to provide interactions with AHR.  However, a 
para substitution seems to abolish the interaction (Figure 4.5). 
The antagonistic activities of the compounds containing 2-fluorophenyl (48), 2-
chlorophenyl (49) and 2-methyloxyphenyl (50) structures were not comparable to the 
parent compound. As a whole, most compounds in the library did not exert higher 
activity than that of compound 36, except compound 51, which showed a comparable 
activity to that of compound 36.  Compound 51 appears to be slightly more agonistic than 
36 with 2-methlyphenyl A ring group (Figure 4.5). 
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4.2.3 Ring B optimization and fine tuning 
 
 As A and C rings have been optimized with 2-methylphenyl and pyridine-2-
carbonyl group, respectively, B ring was next investigated. To examine the role of 2-
methyl group on B ring on the parent compound‟s activity, the 2-methyl group on 36 was 
moved to 3- position (52), removed (53), or replaced with an ethyl group (54) and 
evaluated for its impact on the AHR activity (Figure 4.6).   
 
 
 
Figure 4.6 Synthetic scheme and the resulting library of diphenyldiazenyl picolinic 
carboxamides 
  
 All compounds prepared were not significant different from the parent compound 
(36).  Based on these observations, 2-methylphenyl group is decided for the B ring.  
Further, the importance of methyl groups on A ring was confirmed by comparing the 
activities of compounds 53 and 56.  Compound (56) lacking methyl group on A ring 
completely lost its activity, supporting the importance of A ring methyl group  (Figure 
4.7).  
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4.2.4 Antagonistic evaluation of diphenyldiazenyl amines 
 
Figure 4.7 Synthetic scheme and the resulting library of diphenyldiazenyl amines 
 
 The diphenyldiazenyl amine structures were prepared as intermediates for the 
syntheses of carboxamides. These aromatic compounds were tested whether they have 
any activity against the AHR.  Overall, the loss of AHR antagonistic activity was 
observed for all of these compounds except compound 59. This indicates the important 
role of C ring in the action of the parent compound.  Unlike other two ring compounds, 
59 exhibited modest antagonistic activity.  Furthermore, this compound synergistically 
increased AHR activation in concert with TCDD.  On the other hand, several two ring 
compounds, such as 57, 61, 65 and 66, exhibited AHR agonistic activities (Figure 4.7).  
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4.3 Discussion 
 
To identify a novel AHR ligand, the positional scanning approach was used to 
optimize a parent compound CH-223191 in this chapter.  Commencing with the 
substitution of 1-methyl-1H-pyrazole on C ring with various structures, C ring, A ring 
and B ring were optimized in order, identifying several compounds as antagonist or 
agonists.  As the diphenyldiazenyl structure and an isosteric structure, stilbene, are 
frequently found in chemical agents exerting various biological activity suggesting the 
significance of this feature (97, 123, 137-142), the diphenyldiazenyl structure was 
conserved throughout the library due to the presumable role in the interaction with AHR.  
The SAR studies reveal the optimal structure within the library generated herein.  
As shown above, heterocyclic ring structure, such as 1-methyl-1H-pyrazole (26), pyridine 
(36), furan (31) and pyrazine (37), appeared to be optimal in the C ring position for 
antagonistic activity while non aromatic structure (32, 33) attenuated both agonistic and 
antagonistic activities.  To our surprise, the pyrrole and indole moiety, frequently found 
in endogenous ligands of AHR, did not increase the interaction with AHR.  Beside, the 
pyrene and naphthalene structure, which are strong agonists, did not appear to increase 
the interaction with AHR, either.   
The SAR on A and B ring revealed that methyl groups on ortho position on both 
rings are optimal for antagonistic activity (36, 44 and 45).  Interestingly, it was found that 
the structural changes in methyl group on B ring were not important for interaction with 
AHR, whereas the concomitant shift on A ring of the same scaffold abolished the 
antagonistic activity.  The role of B ring structure for AHR binding is yet to be elucidated.  
Interestingly, the partial structure of inactive compound (60) exhibited moderate 
antagonistic activity whereas diphenyldiazenyl amines lost the antagonistic activities 
observed in the corresponding three ring structures in general. 
 In conclusion, CH-223191 was optimized by positional scanning, identifying 36 
as an optimized compound.  The further biological activities of this compound are yet to 
be elucidated for better understanding on the ligand binding on AHR.  This compound is 
subjected to the synthesis of a PROTAC that targets AHR. 
  
57 
 
4.4 Syntheses of compounds  
 
Syntheses of aryl carboxamides of o-tolyldiazenyl-o-toluidine 
 
N-[2-methyl-4-[(2-methylphenyl)diazenyl]phenyl]-1H-pyrrole-2-carboxamide (27) 
To a solution of pyrrole-2-carboxylic acid (24.7 mg, 0.2219 mmol) in methylene 
chloride (CH2Cl2; 0.5 ml) was added dichlorotriphenylphosphorane (PPh3Cl2; 74.0 mg, 
0.2219 mmol) and a drop of diisopropylethylamine. After stirring at room temperature for 
30 min, the reaction mixture was added 57 (10.0 mg, 0.0444 mmol) and stirred for 1h. 
The resulting mixture was concentrated under vacuum and subjected to flash column 
chromatography (CH2Cl2) yielding 27 (3.8 mg, 29 %) as a yellowish solid.  
 
 
1H NMR: δ = 8.29 (d, J = 8.7 Hz, 1H), 7.88 (dd, J = 8.7, 2.1  Hz, 1H), 7.81 (s, 1H), 7.63 
(s, 1H), 7.60 (d, J = 4.2 Hz, 2H), 7.34 (m, 2H), 7.04 (m, 1H), 6.74 (m, 1H), 6.33 (q, J = 
3.9 Hz, 1H), 2.73 (s, 3H), 2.45 (s, 3H) ppm.  Mass calcd. for [M] 318.15, found (ES) [M] 
318. 
 
 
1-Methyl-N-[2-methyl-4-[(2-methylphenyl)diazenyl]phenyl]-1-methyl-pyrrole-2-
carboxamide (28) 
To a solution of 1-methyl pyrrole-2-carboxylic acid (27.8 mg, 0.2219 mmol) in 
methylene chloride (CH2Cl2; 0.5 ml) was added dichlorotriphenylphosphorane (PPh3Cl2; 
74.0 mg, 0.2219 mmol) and a drop of diisopropylethylamine. After stirring at room 
temperature for 30 min, the reaction mixture was added 57 (10.0 mg, 0.0444 mmol) and 
stirred for 1h.The resulting mixture was concentrated under vacuum and subjected to 
flash column chromatography (CH2Cl2) yielding 28 (1.0 mg, 7 %) as a yellowish solid.   
 
1H NMR: δ = 8.30 (d, J = 8.7 Hz, 1H), 7.88 (dd, Ja = 2.1 Hz, Jb = 8.7 Hz, 1H), 7.81 (s, 
1H), 7.63 (d, J = 8.7 Hz, 2H), 7.36 (m, 2H), 6.85 (t, J = 1.8 Hz, 1H), 6.76 (dd, Ja = 1.5 
Hz, Jb = 3.6 Hz, 1H), 6.20 (dd, Ja = 2.7 Hz, Jb = 3.9 Hz, 1H), 4.02(s, 3H), 2.73 (s, 3H), 
2.44(s, 3H) ppm.  Mass calcd. for [M] 332.16, found (ES) [M] 332. 
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N-[2-methyl-4-[(2-methylphenyl)diazenyl]phenyl]-benzamide (29) 
To a solution of benzoic acid (27.1 mg, 0.2219 mmol) in methylene chloride 
(CH2Cl2; 0.5 ml) was added dichlorotriphenylphosphorane (PPh3Cl2; 74.0 mg, 0.2219 
mmol) and a drop of diisopropylethylamine. After stirring at room temperature for 30 
min, the reaction mixture was added 57 (10.0 mg, 0.0444 mmol) and stirred for 1h.The 
resulting mixture was concentrated under vacuum and subjected to flash column 
chromatography (CH2Cl2) yielding 29 (11.7 mg, 80 %) as a yellowish solid.   
 
1H NMR: δ = 8.35 (d, J = 8.7 Hz, 1H), 7.94 (t, J = 1.8 Hz, 1H), 7.92 (m, 1H), 7.90 (dd, Ja 
= 2.1 Hz, Jb = 8.7 Hz, 1H), 7.83 (s, 1H), 7.65 (dd, Ja = 7.5 Hz, Jb = 12.0 Hz, 2H), 7.59 (m, 
2H), 7.37 (m, 2H), 7.31(m, 1H),  2.73 (s, 3H), 2.44(s, 3H) ppm.  Mass calcd. for [M] 
329.15, found (ES) [M] 329. 
 
 
2-Methyl-N-[2-methyl-4-[(2-methylphenyl)diazenyl]phenyl]-benzamide (30) 
To a solution of o-toluic acid (30.2 mg, 0.2219 mmol) in methylene chloride 
(CH2Cl2; 0.5 ml) was added dichlorotriphenylphosphorane (PPh3Cl2; 74.0 mg, 0.2219 
mmol) and a drop of diisopropylethylamine. After stirring at room temperature for 30 
min, the reaction mixture was added 57 (10.0 mg, 0.0444 mmol) and stirred for 1h.The 
resulting mixture was concentrated under vacuum and subjected to flash column 
chromatography (CH2Cl2) yielding 30 (14.5 mg, 95 %) as a yellowish solid.   
 
1
H NMR: δ = 8.30 (dd, Ja = 1.5 Hz, Jb = 6.6 Hz, 1H ), 7.88 (d, J = 9.0 Hz, 1H), 7.81 (d, J 
= 1.8 Hz, 1H), 7.63 (d, J = 7.8 Hz, 1H), 7.55 (d, J = 7.8 Hz, 1H) , 7.44-7.23 (m, 6H), 2.72 
(s, 3H), 2.56 (s, 3H), 2.44(s, 3H) ppm.  Mass calcd. for [M] 343.17, found (ES) [M] 343. 
 
N-[2-methyl-4-[(2-methylphenyl)diazenyl]phenyl]-2-furancarboxamide (31) 
To a solution of 2-furoic acid (24.9 mg, 0.2219 mmol) in methylene chloride 
(CH2Cl2; 0.5 ml) was added dichlorotriphenylphosphorane (PPh3Cl2; 74.0 mg, 0.2219 
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mmol) and a drop of diisopropylethylamine. After stirring at room temperature for 30 
min, the reaction mixture was added 57 (10.0 mg, 0.0444 mmol) and stirred for 1h.The 
resulting mixture was concentrated under vacuum and subjected to flash column 
chromatography (CH2Cl2) yielding 31 (8.6 mg, 61 %) as a yellowish solid.   
 
1H NMR: δ = 7.87 (s, 1H), 7.78 (dd, Ja = 2.4 Hz, Jb = 8.4 Hz, 1H ), 7.63 (d, J = 7.8 Hz, 
1H), 7.48 (m, 1H), 7.42-7.26 (m, 2H), 7.05 (d, 1H), 6.47 (m, 2H), 6.34 (s, 1H), 2.72 (s, 
3H),  2.41 (s, 12H) ppm.  Mass calcd. for [M] 319.13, found (ES) [M] 319. 
 
 
N-[2-methyl-4-[(2-methylphenyl)diazenyl]phenyl]-cyclopentanecarboxamide (32) 
To a solution of cyclopentylcarboxylic acid (9.6 µL, 0.2219 mmol) in methylene 
chloride (CH2Cl2; 0.5 ml) was added dichlorotriphenylphosphorane (PPh3Cl2; 74.0 mg, 
0.2219 mmol) and a drop of diisopropylethylamine. After stirring at room temperature for 
30 min, the reaction mixture was added 57 (10.0 mg, 0.0444 mmol) and stirred for 
1h.The resulting mixture was concentrated under vacuum and subjected to flash column 
chromatography (CH2Cl2) yielding 32 (14.0 mg, 98 %) as a yellowish solid.   
 
1H NMR: δ = 8.23 (d, J = 8.4, 1H ), 7.84(dd, Ja = 2.1 Hz, Jb = 8.4 Hz, 1H ), 7.78 (d, J = 
1.8 Hz, 1H), 7.63 (d, J = 7.5 Hz, 2H), 7.36-7.32 (m, 2H), 7.29-7.24 (m, 1H), 7.13 (m, 
1H), 2.81 (quintet, J = 8.1 Hz, 1H), 2.73 (s, 3H), 2.37 (s, 3H), 2.00-1.61(m, 8H) ppm.  
Mass calcd. for [M] 321.18, found (ES) [M] 321. 
 
 
N-[2-methyl-4-[(2-methylphenyl)diazenyl]phenyl]-cyclohexanecarboxamide (33) 
 To a solution of cyclohexylcarboxylic acid (11 µL, 0.2219 mmol) in methylene 
chloride (CH2Cl2; 0.5 ml) was added dichlorotriphenylphosphorane (PPh3Cl2; 74.0 mg, 
0.2219 mmol) and a drop of diisopropylethylamine. After stirring at room temperature for 
30 min, the reaction mixture was added 57 (10.0 mg, 0.0444 mmol) and stirred for 
1h.The resulting mixture was concentrated under vacuum and subjected to flash column 
chromatography (CH2Cl2) yielding 33 (12.9 mg, 87 %) as a yellowish solid.   
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1H NMR: δ = 8.23 (d, J = 8.4 Hz, 1H ), 7.84(dd, Ja = 2.1 Hz, Jb = 8.4 Hz, 1H ), 7.81 (d, J 
= 1.8 Hz, 1H), 7.62 (d, J = 7.5 Hz, 2H), 7.36-7.33 (m, 2H), 7.26-7.18 (m, 1H), 7.14 (m, 
1H), 2.72 (s, 3H), 2.38 (s, 3H), 2.35-1.26(m, 10H) ppm.  Mass calcd. for [M] 335.20, 
found (ES) [M] 335. 
 
 
N-[2-methyl-4-[(2-methylphenyl)diazenyl]phenyl]-1H-indole-2-carboxamide (34) 
To a solution of 1H-indole-2-carboxylic acid (35.8 mg, 0.2219 mmol) in 
methylene chloride (CH2Cl2; 0.5 ml) was added dichlorotriphenylphosphorane (PPh3Cl2; 
74.0 mg, 0.2219 mmol) and a drop of diisopropylethylamine. After stirring at room 
temperature for 30 min, the reaction mixture was added 57 (10.0 mg, 0.0444 mmol) and 
stirred for 1h.The resulting mixture was concentrated under vacuum and subjected to 
flash column chromatography (CH2Cl2) yielding 34 (1.0 mg, 6 %) as a yellowish solid.   
 
1H NMR: δ = 8.36 (d, J = 8.7 Hz, 1H), 7.89 (m, 3H), 7.74(d, J = 8.7 Hz, 1H),  7.65 (d, J 
= 7.8 Hz, 1H), 7.51 (d, J = 7.8 Hz, 1H), 7.35 (m, 3H), 7.26-7.18 (m, 1H), 7.04 (s, 1H),  
2.74 (s, 3H), 2.52 (s, 3H) ppm.  Mass calcd. for [M] 368.16, found (ES) [M] 368. 
 
 
1-Methyl-N-[2-methyl-4-[(2-methylphenyl)diazenyl]phenyl]-indole-2-carboxamide (35) 
To a solution of 1-methylindole-2-carboxylic acid (38.9 mg, 0.2219 mmol) in 
methylene chloride (CH2Cl2; 0.5 ml) was added dichlorotriphenylphosphorane (PPh3Cl2; 
74.0 mg, 0.2219 mmol) and a drop of diisopropylethylamine. After stirring at room 
temperature for 30 min, the reaction mixture was added 57 (10.0 mg, 0.0444 mmol) and 
stirred for 1h.The resulting mixture was concentrated under vacuum and subjected to 
flash column chromatography (CH2Cl2) yielding 35 (4.0 mg, 24 %) as a yellowish solid.   
 
1H NMR: δ = 8.37 (d, J = 8.7 Hz, 1H ), 7.94-7.88 (m, 2H), 7.85(s, 1H), 7.73 (d, J = 8.4 
Hz, 1H), 7.66 (d, J = 8.4 Hz, 1H), 7.45-7.40 (m, 2H), 7.36 (m, 2H), 7.29-7.19 (m, 1H), 
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7.14 (m, 1H), 4.14 (s, 3H), 2.75 (s, 3H), 2.49 (s, 3H) ppm.  Mass calcd. for [M] 382.18, 
found (ES) [M] 382. 
 
 
N-[2-methyl-4-[(2-methylphenyl)diazenyl]phenyl]-2-pyridinecarboxamide (36) 
To a solution of 2-picolinic acid (27.3 mg, 0.2219 mmol) in methylene chloride 
(CH2Cl2; 0.5 ml) was added dichlorotriphenylphosphorane (PPh3Cl2; 74.0 mg, 0.2219 
mmol) and a drop of diisopropylethylamine. After stirring at room temperature for 30 
min, the reaction mixture was added 57 (10.0 mg, 0.0444 mmol) and stirred for 1h.The 
resulting mixture was concentrated under vacuum and subjected to flash column 
chromatography (CH2Cl2) yielding 36 (3.6 mg, 25 %) as a yellowish solid.  
 
1H NMR: δ = 8.67 (d, J = 4.5 Hz, 1H), 8.63 (d, J = 9.0 Hz, 1H),  8.36 (d, J = 8.1 Hz, 1H), 
7.98-7.88 (dq, Ja = 1.6 Hz, Jb = 7.5 Hz, 2H ), 7.84 (s, 1H),  7.64 (d, J = 8.4 Hz, 1H), 7.54 
(m, 1H) 7.36 (m, 2H), 7.30 (m, 1H), 2.74 (s, 3H), 2.56 (s, 3H) ppm.  Mass calcd. for [M] 
330.15, found (ES) [M] 330. 
 
 
N-[2-methyl-4-[(2-methylphenyl)diazenyl]phenyl]-pyrazinecarboxamide (37) 
To a solution of pyrazinecarboxylic acid (27.6 mg, 0.2219 mmol) in methylene 
chloride (CH2Cl2; 0.5 ml) was added dichlorotriphenylphosphorane (PPh3Cl2; 74.0 mg, 
0.2219 mmol) and a drop of diisopropylethylamine. After stirring at room temperature for 
30 min, the reaction mixture was added 33 (10.0 mg, 0.0444 mmol) and stirred for 
1h.The resulting mixture was concentrated under vacuum and subjected to flash column 
chromatography (CH2Cl2) yielding 37 (9.8 mg, 67 %) as a yellowish solid.   
 
1H NMR: δ = 9.56 (d, J = 1.5 Hz, 1H), 8.85 (d, J = 2.1 Hz, 1H), 8.63 (t, J = 2.1 Hz, 1H), 
8.57 (d, J = 8.7 Hz, 1H),  7.91 (dd, Ja = 2.1 Hz, Jb = 8.7 Hz, 1H ), 7.83 (d, J = 1.8 Hz, 
1H), 7.61 (d, J = 7.5 Hz, 1H), 7.36 (m, 2H), 7.29 (m, 1H), 2.73 (s, 3H), 2.53 (s, 3H) ppm.  
Mass calcd. for [M] 331.14, found (ES) [M] 331. 
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N-[2-methyl-4-[(2-methylphenyl)diazenyl]phenyl]-1-naphthalenecarboxamide (38) 
To a solution of 1-naphthoic acid (38.2 mg, 0.2219 mmol) in methylene chloride 
(CH2Cl2; 0.5 ml) was added dichlorotriphenylphosphorane (PPh3Cl2; 74.0 mg, 0.2219 
mmol) and a drop of diisopropylethylamine. After stirring at room temperature for 30 
min, the reaction mixture was added 57 (10.0 mg, 0.0444 mmol) and stirred for 1h.The 
resulting mixture was concentrated under vacuum and subjected to flash column 
chromatography (CH2Cl2) yielding 38 (10.5 mg, 63 %) as a yellowish solid.   
 
1H NMR: δ = 8.45 (d, J = 7.8 Hz, 2H), 8.02 (d, J = 9.0 Hz, 1H), 7.92 (m, 2H), 7.82 (m, 
1H), 7.79 (s, 1H), 7.68-7.51 (m, 4H), 7.36 (m, 2H), 7.30 (m, 1H),   2.74 (s, 3H), 2.40 (s, 
3H) ppm.  Mass calcd. for [M] 379.17, found (ES) [M] 379. 
 
 
2-Methyl-N-[2-methyl-4-[(2-methylphenyl)diazenyl]phenyl]-1-naphthalenecarboxamide 
(39) 
To a solution of 2-methyl-1-naphthoic acid (41.3 mg, 0.2219 mmol) in methylene 
chloride (CH2Cl2; 0.5 ml) was added dichlorotriphenylphosphorane (PPh3Cl2; 74.0 mg, 
0.2219 mmol) and a drop of diisopropylethylamine. After stirring at room temperature for 
30 min, the reaction mixture was added 57 (10.0 mg, 0.0444 mmol) and stirred for 
1h.The resulting mixture was concentrated under vacuum and subjected to flash column 
chromatography (CH2Cl2) yielding 39 (3.6 mg, 21 %) as a yellowish solid.   
 
1H NMR: δ = 8.27 (d, J = 8.7 Hz, 2H), 7.95 (s, 1H), 7.89 (dd, Ja = 0.9 Hz, Jb = 9.9 Hz, 1H 
), 7.80 (d, J = 6.6 Hz, 2H), 7.69-7.34 (m, 4H), 7.31 (m, 1H), 7.00 (m, 2H), 2.74 (s, 3H), 
2.70 (s, 6H) ppm.  Mass calcd. for [M] 393.18, found (ES) [M] 393. 
 
 
N-[2-methyl-4-[(2-methylphenyl)diazenyl]phenyl]-5-Acenaphthenecarboxamide (40) 
To a solution of 5-acenaphthene carboxylic acid (44.0 mg, 0.2219 mmol) in 
methylene chloride (CH2Cl2; 0.5 ml) was added dichlorotriphenylphosphorane (PPh3Cl2; 
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74.0 mg, 0.2219 mmol) and a drop of diisopropylethylamine. After stirring at room 
temperature for 30 min, the reaction mixture was added 57 (10.0 mg, 0.0444 mmol) and 
stirred for 1h.The resulting mixture was concentrated under vacuum and subjected to 
flash column chromatography (CH2Cl2) yielding 40 (6.0 mg, 33 %) as a yellowish solid.   
 
1H NMR: δ = 8.48 (d, J = 8.1 Hz, 1H), 8.27 (d, J = 8.7 Hz, 1H), 7.93 (m, 2H), 7.84 (s, 
1H), 7.77 (s, 1H), 7.69 (m, 2H), 7.42 (d, J = 6.6 Hz, 1H), 7.37 (m, 2H), 7.31 (m, 1H), 
3.47 (s. 4H), 2.75 (s, 3H), 2.43 (s, 3H) ppm.  Mass calcd. for [M] 405.18, found (ES) [M] 
405. 
 
 
N-[2-methyl-4-[(2-methylphenyl)diazenyl]phenyl]-9-anthracenecarboxamide (41) 
To a solution of 9-anthracenecarboxylic acid (49.3 mg, 0.2219 mmol) in 
methylene chloride (CH2Cl2; 0.5 ml) was added dichlorotriphenylphosphorane (PPh3Cl2; 
74.0 mg, 0.2219 mmol) and a drop of diisopropylethylamine. After stirring at room 
temperature for 30 min, the reaction mixture was added 57 (10.0 mg, 0.0444 mmol) and 
stirred for 1h.The resulting mixture was concentrated under vacuum and subjected to 
flash column chromatography (CH2Cl2) yielding 41 (14.3 mg, 75 %) as a yellowish solid.   
 
1H NMR: δ = 8.65 (d, J = 9.0 Hz, 1H), 8.55 (s, 1H), 8.22 (d, J = 8.5 Hz, 2H), 8.07 (d, J = 
9.0 Hz, 2H), 7.97, (d, J = 8.5 Hz, 1H), 7.81(s, 1H), 7.66 (m, 2H), 7.58-7.47 (m, 4H), 7.36 
(m, 2H), 7.26 (m, 1H), 2.75 (s, 3H), 2.30 (s, 3H) ppm.  Mass calcd. for [M] 429.18, found 
(ES) [M] 429. 
 
 
N-[2-methyl-4-[(2-methylphenyl)diazenyl]phenyl]-1-pyrenecarboxamide (42) 
To a solution of 1-pyrenecarboxylic acid (54.7 mg, 0.2219 mmol) in methylene 
chloride (CH2Cl2; 0.5 ml) was added dichlorotriphenylphosphorane (PPh3Cl2; 74.0 mg, 
0.2219 mmol) and a drop of diisopropylethylamine. After stirring at room temperature for 
30 min, the reaction mixture was added 57 (10.0 mg, 0.0444 mmol) and stirred for 
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1h.The resulting mixture was concentrated under vacuum and subjected to flash column 
chromatography (CH2Cl2) yielding 42 (12.4 mg, 62 %) as a yellowish solid.   
 
1H NMR: δ = 8.64 (d, J = 9.0 Hz, 1H), 8.32-8.27 (m, 2H), 8.23-8.10 (m, 5H), 8.08-8.01 
(m, 2H), 7.85 (m, 1H), 7.79, (s, 1H), 7.57 (d, J = 8.0 Hz, 1H), 7.30-7.28 (m, 2H), 7.25-
7.20 (m, 1H), 2.67 (s, 3H), 2.41 (s, 3H) ppm.  Mass calcd. for [M] 453.18, found (ES) 
[M] 453. 
 
 
N-[2-methyl-4-[(2-methylphenyl)diazenyl]phenyl]-noradamantane-3-carboxamide (43) 
To a solution of 3-noradamantane carboxylic acid (36.9 mg, 0.2219 mmol) in 
methylene chloride (CH2Cl2; 0.5 ml) was added dichlorotriphenylphosphorane (PPh3Cl2; 
74.0 mg, 0.2219 mmol) and a drop of diisopropylethylamine. After stirring at room 
temperature for 30 min, the reaction mixture was added 57 (10.0 mg, 0.0444 mmol) and 
stirred for 1h.The resulting mixture was concentrated under vacuum and subjected to 
flash column chromatography (CH2Cl2) yielding 43 (6.0 mg, 36 %) as a yellowish solid.   
 
1H NMR: δ = 8.33 (d, J = 8.7 Hz, 1H), 7.85 (dd, Ja = 0.9 Hz, Jb = 9.9 Hz, 1H), 7.77 (d, J 
= 6.6 Hz, 1H), 7.62 (d, J = 7.5 Hz, 1H), 7.37-7.33 (m, 2H), 7.26 (m, 1H), 2.86 (t, J = 6.3 
Hz, 1H), 2.72 (s, 3H), 2.42 (s, 2H), 2.37 (s, 3H), 2.17 (dd, Ja = 2.7 Hz, Jb = 10.8 Hz, 2H), 
1.97-1.89 (m, 4H), 1.75-1.63 (m, 4H) ppm.  Mass calcd. for [M] 373.22, found (ES) [M] 
373. 
 
 
Synthesis of aminodiazenes (I) 
 
p-(o-Tolyldiazenyl)-o-toluidine (57) 
To a solution of hydrochloric acid (2 N, 5 ml) was added o-toluidine (1.0716 g, 
10.0 mmol). The resulting ammonium solution salt was cooled to 0~5 °C and to this was 
gradually added NaNO2 (0.828 g, 12.0 mmol) and stirred for 2 h. To the reaction mixture 
was added o-toluidine (1.0716 g, 10.0 mmol).  The reaction mixture was then allowed to 
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come up to room temperature and stirred for 10 min. To the mixture was then added 
NaHCO3 (aqueous solution, 1 M; until pH = 8~9). The precipitates were extracted with 
CH2Cl2, concentrated under vacuum and subjected to flash column chromatography (100 
% CH2Cl2) yielding 57 (810 mg, 36 %) as a reddish solid.   
 
1H NMR: δ = 7.71 (d, J = 7.5 Hz, 2H), 7.57 (dd, Ja = 7.5 Hz, Jb = 1.0 Hz, 1H), 7.29 (m, 
2H), 7.25 (m, 1H), 6.46 (dd, Ja = 8.0 Hz, Jb = 1.0 Hz, 1H), 2.68 (s, 3H), 2.24 (s, 3H) ppm.  
Mass calcd. for [M] 225.13, found (ES) [M] 225. 
 
 
p-(m-tolyldiazenyl)-o-toluidine (58)  
To a solution of hydrochloric acid was added m-toluidine (24.0 mg, 0.2239 
mmol). The resulting ammonium solution salt was cooled to 0~5 °C and to this was 
gradually added NaNO2 (20.00 mg, 0.2899 mmol) and stirred for 2 h. To the reaction 
mixture was added o-toluidine (20.0 mg, 0.1866 mmol). The reaction mixture was then 
allowed to come up to room temperature and stirred for 10 min. To the mixture was then 
added NaHCO3 (aqueous solution, 1 M; until pH = 8~9). The precipitates were extracted 
with CH2Cl2, concentrated under vacuum and subjected to flash column chromatography 
(100 % CH2Cl2) yielding 58 (12.0 mg, 29 %) as a reddish solid.   
 
1H NMR: δ = 7.76 (d, J = 7.5 Hz, 2H), 7.71 (dd, Ja = 8.5 Hz, Jb = 1.0 Hz, 1H), 7.57 (dd, 
Ja = 8.0 Hz, Jb = 1.0 Hz, 1H), 7.32 (m, 2H), 7.26 (m, 1H), 6.88 (d, J = 8.5 Hz, 1H), 2.70 
(s, 3H), 2.34 (s, 3H) ppm.  Mass calcd. for [M] 225.13, found (ES) [M] 225. 
 
 
p-(p-tolyldiazenyl)-o-toluidine (59)  
To a solution of hydrochloric acid was added p-toluidine (20.0 mg, 0.1866 mmol). 
The resulting ammonium solution salt was cooled to 0~5 °C and to this was gradually 
added NaNO2 (20.00 mg, 0.2899 mmol) and stirred for 2 h. To the reaction mixture was 
added o-toluidine (20.0 mg, 0.1866 mmol). The reaction mixture was then allowed to 
come up to room temperature and stirred for 10 min. To the mixture was then added 
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NaHCO3 (aqueous solution, 1 M; until pH = 8~9). The precipitates were extracted with 
CH2Cl2, concentrated under vacuum and subjected to flash column chromatography (100 
% CH2Cl2) yielding 59 (12.0 mg, 29 %) as a reddish solid.   
 
1H NMR: δ = 7.79 (d, J = 8.0 Hz, 2H), 7.73 (m, 2H), 7.31 (d, J = 8.0 Hz, 2H), 6.76 (d, J 
= 8.5 Hz, 1H), 2.44 (s, 3H), 2.25 (s, 3H) ppm.  Mass calcd. for [M] 225.13, found (ES) 
[M] 225. 
 
 
p-(phenyldiazenyl)-o-toluidine (60)  
To a solution of hydrochloric acid was added aniline (17.4 mg, 0.1866 mmol). 
The resulting ammonium solution salt was cooled to 0~5 °C and to this was gradually 
added NaNO2 (20.00 mg, 0.2899 mmol) and stirred for 2 h. To the reaction mixture was 
added o-toluidine (20.0 mg, 0.1866 mmol). The reaction mixture was then allowed to 
come up to room temperature and stirred for 10 min. To the mixture was then added 
NaHCO3 (aqueous solution, 1 M; until pH = 8~9). The precipitates were extracted with 
CH2Cl2, concentrated under vacuum and subjected to flash column chromatography (100 
% CH2Cl2) yielding 60 (12.4 mg, 32 %) as a reddish solid.   
 
1H NMR: δ = 7.89 (dd, Ja = 8.5 Hz, Jb = 0.5 Hz, 2H), 7.75 (m, 2H), 7.52 (m, 2H), 7.44 
(m, 1H), 6.76 (m, 1H), 2.26 (s, 3H) ppm.  Mass calcd. for [M] 211.11, found (ES) [M] 
211. 
 
 
p-(o-ethylphenyldiazenyl)-o-toluidine (61)  
To a solution of hydrochloric acid was added 2-ethylaniline (22.6 mg, 0.1866 
mmol). The resulting ammonium solution salt was cooled to 0~5 °C and to this was 
gradually added NaNO2 (20.00 mg, 0.2899 mmol) and stirred for 2 h. To the reaction 
mixture was added o-toluidine (20.0 mg, 0.1866 mmol). The reaction mixture was then 
allowed to come up to room temperature and stirred for 10 min. To the mixture was then 
added NaHCO3 (aqueous solution, 1 M; until pH = 8~9). The precipitates were extracted 
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with CH2Cl2, concentrated under vacuum and subjected to flash column chromatography 
(100 % CH2Cl2) yielding 61 (4.7 mg, 11 %) as a reddish solid.   
 
1H NMR: δ = 7.80 (d, J = 2.5 Hz, 1H), 7.73 (m, 1H), 7.60 (m, 1H), 7.37 (m, 2H), 7.28 
(m, 1H), 2.75 (m, 2H), 2.70 (s, 3H), 1.37 (s, 3H) ppm.  Mass calcd. for [M] 239.14, found 
(ES) [M] 239. 
 
 
p-(o-fluorophenyldiazenyl)-o-toluidine (62)  
To a solution of hydrochloric acid was added o-fluoroaniline (20.7 mg, 0.1866 
mmol). The resulting ammonium solution salt was cooled to 0~5 °C and to this was 
gradually added NaNO2 (20.00 mg, 0.2899 mmol) and stirred for 2 h. To the reaction 
mixture was added o-toluidine (20.0 mg, 0.1866 mmol). The reaction mixture was then 
allowed to come up to room temperature and stirred for 10 min. To the mixture was then 
added NaHCO3 (aqueous solution, 1 M; until pH = 8~9). The precipitates were extracted 
with CH2Cl2, concentrated under vacuum and subjected to flash column chromatography 
(100 % CH2Cl2) yielding 62 (27.0 mg, 63 %) as a reddish solid.   
 
1H NMR: δ = 7.67 (s, 2H), 7.65 (m, 1H), 7.27 (m, 1H), 7.17 (m, 2H), 6.65 (d, J = 8.5 Hz, 
1H), 6.76 (d, J = 8.5 Hz, 1H), 2.14 (s, 3H) ppm.  Mass calcd. for [M] 229.10, found (ES) 
[M] 229. 
 
 
p-(o-chlorophenyldiazenyl)-o-toluidine (63)  
To a solution of hydrochloric acid was added o-chloroaniline (23.8 mg, 0.1866 
mmol). The resulting ammonium solution salt was cooled to 0~5 °C and to this was 
gradually added NaNO2 (20.00 mg, 0.2899 mmol) and stirred for 2 h. To the reaction 
mixture was added o-toluidine (20.0 mg, 0.1866 mmol). The reaction mixture was then 
allowed to come up to room temperature and stirred for 10 min. To the mixture was then 
added NaHCO3 (aqueous solution, 1 M; until pH = 8~9). The precipitates were extracted 
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with CH2Cl2, concentrated under vacuum and subjected to flash column chromatography 
(100 % CH2Cl2) yielding 63 (20.0 mg, 44 %) as a reddish solid.   
 
1H NMR: δ = 7.75 (d, J = 7.5 Hz, 2H), 7.65 (d, J = 9.5 Hz, 1H), 7.51(d, J = 9.0 Hz, 1H), 
7.30 (m, 2H), 6.71 (d, J = 8.5 Hz, 1H), 2.21 (s, 3H) ppm.  Mass calcd. for [M] 245.07, 
found (ES) [M] 245. 
 
 
p-(o-methoxyphenyldiazenyl)-o-toluidine (64)  
To a solution of hydrochloric acid was added o-anisidine (24.0 mg, 0.1866 
mmol). The resulting ammonium solution salt was cooled to 0~5 °C and to this was 
gradually added NaNO2 (20.00 mg, 0.2899 mmol) and stirred for 2 h. To the reaction 
mixture was added o-toluidine (20.0 mg, 0.1866 mmol). The reaction mixture was then 
allowed to come up to room temperature and stirred for 10 min. To the mixture was then 
added NaHCO3 (aqueous solution, 1 M; until pH = 8~9). The precipitates were extracted 
with CH2Cl2, concentrated under vacuum and subjected to flash column chromatography 
(100 % CH2Cl2) yielding 64 (12.2 mg, 27.1%) as a reddish solid.   
 
1H NMR: δ = 7.70 (d, J = 7.5 Hz, 2H), 7.62 (dd, Ja = 8.0 Hz, Jb = 1.5 Hz, 1H), 7.35 (m, 
1H), 7.05 (d, J = 8.5 Hz, 1H), 7.00 (m, 1H), 6.71 (d, J = 8.0 Hz, 1H), 4.00 (s, 3H), 2.22 
(s, 3H) ppm.  Mass calcd. for [M] 241.12, found (ES) [M] 241. 
 
 
p-(1-naphthyldiazenyl)-o-toluidine (65)  
To a solution of hydrochloric acid was added 1-naphthylamine (26.7 mg, 0.1866 
mmol). The resulting ammonium solution salt was cooled to 0~5 °C and to this was 
gradually added NaNO2 (20.00 mg, 0.2899 mmol) and stirred for 2 h. To the reaction 
mixture was added o-toluidine (20.0 mg, 0.1866 mmol). The reaction mixture was then 
allowed to come up to room temperature and stirred for 10 min. To the mixture was then 
added NaHCO3 (aqueous solution, 1 M; until pH = 8~9). The precipitates were extracted 
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with CH2Cl2, concentrated under vacuum and subjected to flash column chromatography 
(100 % CH2Cl2) yielding 65 (4.0 mg, 8.2%) as a reddish solid.   
 
1H NMR: δ = 7.91 (d, J = 8.0 Hz, 2H), 7.85 (m, 2H), 7.75 (dd, Ja = 8.0 Hz, Jb = 2.0 Hz, 
1H), 7.62 (m, 1H), 7.57 (m, 3H), 6.79 (d, J = 8.5 Hz, 1H), 2.29 (s, 3H) ppm.  Mass calcd. 
for [M] 261.13, found (ES) [M] 261. 
 
 
Synthesis of picolinic carboxamides of aminodiazenes (I) 
 
N-[2-methyl-4-[(3-methylphenyl)diazenyl]phenyl]-2-pyridine carboxamide (44) 
To a solution of 2-picolinic acid (16.4 mg, 0.1332 mmol) in methylene chloride 
(CH2Cl2; 0.5 ml) was added dichlorotriphenylphosphorane (PPh3Cl2; 44.4 mg, 0.2219 
mmol) and a drop of diisopropylethylamine. After stirring at room temperature for 30 
min, the reaction mixture was added 58 (6.0 mg, 0.0266 mmol) and stirred for 1h. The 
resulting mixture was concentrated under vacuum and subjected to flash column 
chromatography (100 % CH2Cl2) yielding 44 (2.6 mg, 30 %) as a yellowish solid.   
 
1H NMR: δ = 8.66 (m, 2H), 8.35 (d, J = 7.5 Hz, 1H), 7.97 (m, 2H), 7.93 (m, 1H), 7.83 (s, 
1H), 7.72 (s, 2H), 7.54 (m, 1H), 7.43 (m, 1H), 7.29 (m, 1H) 2.55 (s, 3H), 2.47 (s, 3H) 
ppm.  Mass calcd. for [M] 330.15, found (ES) [M] 330. 
 
 
N-[2-methyl-4-[(4-methylphenyl)diazenyl]phenyl]-2-pyridine carboxamide (45) 
To a solution of 2-picolinic acid (16.4 mg, 0.1332 mmol) in methylene chloride 
(CH2Cl2; 0.5 ml) was added dichlorotriphenylphosphorane (PPh3Cl2; 44.4 mg, 0.1332 
mmol) and a drop of diisopropylethylamine. After stirring at room temperature for 30 
min, the reaction mixture was added 59 (6.0 mg, 0.0266 mmol) and stirred for 1h. The 
resulting mixture was concentrated under vacuum and subjected to flash column 
chromatography (100 % CH2Cl2) yielding 45 (6.0 mg, 68 %) as a yellowish solid.   
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1H NMR: δ = 8.65 (d, J = 10.0 Hz, 1H), 8.62 (d, J = 8.5 Hz, 1H), 8.34 (m, 1H), 7.95 (m, 
1H), 7.88 (m, 1H), 7.83 (m, 3H), 7.52 (m, 1H), 7.32 (d, J = 8.5 Hz, 2H), 2.54 (s, 3H), 
2.44 (s, 3H) ppm.  Mass calcd. for [M] 330.15, found (ES) [M] 330. 
 
 
N-(2-methyl-4-phenyldiazenyl-phenyl)-2-pyridine carboxamide (46) 
To a solution of 2-picolinic acid (18.1 mg, 0.1467 mmol) in methylene chloride 
(CH2Cl2; 0.5 ml) was added dichlorotriphenylphosphorane (PPh3Cl2; 48.9 mg, 0.1467 
mmol) and a drop of diisopropylethylamine. After stirring at room temperature for 30 
min, the reaction mixture was added 60 (6.2 mg, 0.0293 mmol) and stirred for 1h. The 
resulting mixture was concentrated under vacuum and subjected to flash column 
chromatography (100 % CH2Cl2) yielding 46 (4.6 mg, 50 %) as a yellowish solid.  
 
1H NMR: δ = 8.66 (d, J = 4.5 Hz, 1H), 8.63 (d, J = 8.5 Hz, 1H), 8.35 (m, 1H), 7.96 (m, 
1H), 7.92 (m, 4H), 7.84 (m, 1H), 7.54 (m, 2H), 7.48 (m, 1H), 2.55 (s, 3H) ppm.  Mass 
calcd. for [M] 316.13, found (ES) [M] 316. 
 
 
N-[2-methyl-4-[(2-ethylphenyl)diazenyl]phenyl]-2-pyridine carboxamide (47) 
To a solution of 2-picolinic acid (6.4 mg, 0.0522 mmol) in methylene chloride 
(CH2Cl2; 0.5 ml) was added dichlorotriphenylphosphorane (PPh3Cl2; 17.4 mg, 0.0522 
mmol) and a drop of diisopropylethylamine. After stirring at room temperature for 30 
min, the reaction mixture was added 61 (2.5 mg, 0.0104 mmol) and stirred for 1h. The 
resulting mixture was concentrated under vacuum and subjected to flash column 
chromatography (100 % CH2Cl2) yielding 47 (3.5 mg, 97 %) as a yellowish solid.   
 
1H NMR: δ = 8.89 (d, J = 4.5 Hz, 1H), 8.32 (d, J = 8.0 Hz, 1H), 7.97 (m, 2H), 7.85 (m, 
1H), 7.63 (m, 2H), 7.37-7.31 (m, 3H), 7.29 (m, 1H), 2.76 (m, 5H), 1.32 (s, 3H) ppm.  
Mass calcd. for [M + H] 345.17, found (ES) [M + H] 345. 
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N-[2-methyl-4-[(2-fluorophenyl)diazenyl]phenyl]-2-pyridine carboxamide (48) 
To a solution of 2-picolinic acid (24.2 mg, 0.1963 mmol) in methylene chloride 
(CH2Cl2; 0.5 ml) was added dichlorotriphenylphosphorane (PPh3Cl2; 65.4 mg, 0.1963 
mmol) and a drop of diisopropylethylamine. After stirring at room temperature for 30 
min, the reaction mixture was added 62 (9.0 mg, 0.0393 mmol) and stirred for 1h. The 
resulting mixture was concentrated under vacuum and subjected to flash column 
chromatography (100 % CH2Cl2) yielding 48 (7.9 mg, 60 %) as a yellowish solid.   
 
1H NMR: δ = 8.66 (m, 2H), 8.34 (d, J = 7.5 Hz, 1H), 7.96-7.90 (m, 2H), 7.86 (s, 1H), 
7.78 (m, 1H), 7.53 (m, 1H), 7.44 (m, 1H), 7.28 (m, 2H), 2.54 (s, 3H) ppm.  Mass calcd. 
for [M] 334.12, found (ES) [M] 334. 
 
 
N-[2-methyl-4-[(2-chlorophenyl)diazenyl]phenyl]-2-pyridine carboxamide (49) 
To a solution of 2-picolinic acid (25.0 mg, 0.2035 mmol) in methylene chloride 
(CH2Cl2; 0.5 ml) was added dichlorotriphenylphosphorane (PPh3Cl2; 67.8 mg, 0.2035 
mmol) and a drop of diisopropylethylamine. After stirring at room temperature for 30 
min, the reaction mixture was added 63 (10.0 mg, 0.0407 mmol) and stirred for 1h. The 
resulting mixture was concentrated under vacuum and subjected to flash column 
chromatography (100 % CH2Cl2) yielding 49 (10.0 mg, 70 %) as a yellowish solid.   
 
1H NMR: δ = 8.66 (m, 2H), 8.34 (m, 1H), 7.96 (m, 2H), 7.87 (s, 1H), 7.71 (d, J = 8.0 Hz, 
1H), 7.56 (m, 2H), 7.39 (m, 2H), 2.55 (s, 3H) ppm.  Mass calcd. for [M] 350.09, found 
(ES) [M] 350. 
 
 
N-[2-methyl-4-[(2-methoxyphenyl)diazenyl]phenyl]-2-pyridine carboxamide (50) 
To a solution of 2-picolinic acid (15.6 mg, 0.1264 mmol) in methylene chloride 
(CH2Cl2; 0.5 ml) was added dichlorotriphenylphosphorane (PPh3Cl2; 42.1 mg, 0.1264 
mmol) and a drop of diisopropylethylamine. After stirring at room temperature for 30 
min, the reaction mixture was added 64 (6.1 mg, 0.0253 mmol) and stirred for 1h. The 
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resulting mixture was concentrated under vacuum and subjected to flash column 
chromatography (100 % CH2Cl2) yielding 50 (3.2 mg, 37 %) as a yellowish solid.   
 
1H NMR: δ = 8.66 (d, J = 4.5 Hz, 1H), 8.63 (d, J = 9.0 Hz, 1H), 8.34 (d, J = 7.5 Hz, 1H), 
7.96 (m, 2H), 7.83 (s, 1H), 7.69 (d, J = 8.0 Hz, 1H), 7.53 (m, 1H), 7.45 (m, 1H), 7.11 (d, 
J = 8.5 Hz, 1H ), 7.05 (m, 1H), 4.04 (s, 3H), 2.54 (s, 3H) ppm.  Mass calcd. for [M] 
346.14, found (ES) [M] 346. 
 
 
N-[2-methyl-4-(1-naphthyldiazenyl)phenyl]-2-pyridine carboxamide (51)  
To a solution of 2-picolinic acid (4.7 mg, 0.0383 mmol) in methylene chloride 
(CH2Cl2; 0.5 ml) was added dichlorotriphenylphosphorane (PPh3Cl2; 12.8 mg, 0.0383 
mmol) and a drop of diisopropylethylamine. After stirring at room temperature for 30 
min, the reaction mixture was added 65 (2.0 mg, 0.0077 mmol) and stirred for 1h. The 
resulting mixture was concentrated under vacuum and subjected to flash column 
chromatography (100 % CH2Cl2) yielding 51 (1.0 mg, 36 %) as a yellowish solid.   
 
1H NMR: δ = 8.96 (d, J = 8.5 Hz, 1H ), 8.68 (m, 2H), 8.36 (d, J = 7.5 Hz, 1H), 8.04 (d, J 
= 8.5 Hz, 1H), 7.99-7.93 (m, 5H), 7.83 (m, 1H), 7.68 (m, 1H), 7.61 (m, 2H), 7.54 (m, 
1H), 2.56 (s, 3H) ppm.  Mass calcd. for [M] 366.15, found (ES) [M] 366. 
 
 
Synthesis of aminodiazenes (II) 
 
p-(o-tolyldiazenyl)-m-toluidine (66) 
To a solution of hydrochloric acid was added o-toluidine (20.0 mg, 0.1866 mmol). 
The resulting ammonium solution salt was cooled to 0~5 °C and to this was gradually 
added NaNO2 (20.00 mg, 0.2899 mmol) and stirred for 2 h. To the reaction mixture was 
added m-toluidine (20.0 mg, 0.1866 mmol). The reaction mixture was then allowed to 
come up to room temperature and stirred for 10 min. To the mixture was then added 
NaHCO3 (aqueous solution, 1 M; until pH = 8~9). The precipitates were extracted with 
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CH2Cl2, concentrated under vacuum and subjected to flash column chromatography (100 
% CH2Cl2) yielding 66 (10.0 mg, 24 %) as a reddish solid.   
 
1H NMR: δ = 7.66 (d, J = 9.0 Hz, 1H), 7.59 (dd, Ja = 8.0 Hz, Jb = 1.0 Hz, 1H), 7.30 (m, 
2H), 7.25 (m, 1H), 6.59 (d, J = 2.5 Hz, 1H), 6.54 (dd, Ja = 9.0 Hz, Jb = 2.5 Hz, 1H), 2.69 
(s, 3H), 2.67 (s, 3H) ppm.  Mass calcd. for [M] 225.13, found (ES) [M] 225. 
 
 
p-(o-tolyldiazenyl)-aniline (67) 
To a solution of hydrochloric acid was added o-toluidine (19.6 mg, 0.1825 mmol). 
The resulting ammonium solution salt was cooled to 0~5 °C and to this was gradually 
added NaNO2 (18.89 mg, 0.2738 mmol) and stirred for 2 h. To the reaction mixture was 
added aniline (17.0 mg, 0.1828 mmol). The reaction mixture was then allowed to come 
up to room temperature and stirred for 10 min. To the mixture was then added NaHCO3 
(aqueous solution, 1 M; until pH = 8~9). The precipitates were extracted with CH2Cl2, 
concentrated under vacuum and subjected to flash column chromatography (100 % 
CH2Cl2) yielding 67 (5.0 mg, 13 %) as a reddish solid.   
 
1H NMR: δ = 7.85 (m, 3H), 7.72 (m, 1H), 7.50-7.47 (m, 2H), 7.41-7.38 (m, 1H), 6.76 (m, 
2H), 2.25 (s, 3H) ppm.  Mass calcd. for [M] 211.11, found (ES) [M] 211. 
 
 
p-(o-tolyldiazenyl)-o-ethylaniline (68) 
To a solution of hydrochloric acid was added o-toluidine (20.3 mg, 0.1898 mmol). 
The resulting ammonium solution salt was cooled to 0~5 °C and to this was gradually 
added NaNO2 (19.64 mg, 0.2847 mmol) and stirred for 2 h. To the reaction mixture was 
added 2-ethylaniline (23.0 mg, 0.1898 mmol). The reaction mixture was then allowed to 
come up to room temperature and stirred for 10 min. To the mixture was then added 
NaHCO3 (aqueous solution, 1 M; until pH = 8~9). The precipitates were extracted with 
CH2Cl2, concentrated under vacuum and subjected to flash column chromatography (100 
% CH2Cl2) yielding 68 (7.0 mg, 15 %) as a reddish solid.   
74 
 
 
1H NMR: δ = 7.76 (s, 1H), 7.71-7.68 (m, 1H), 7.59 (m, 1H), 7.33 (m, 1H), 7.30 (m, 1H), 
7.26 (m, 1H), 6.76 (m, 1H), 3.15 (q, J = 7.5 Hz, 2H), 2.68(s, 3H), 1.29 (t, J = 7.5 Hz, 3H) 
ppm.  Mass calcd. for [M] 239.14, found (ES) [M] 239. 
 
 
p-(phenyldiazenyl)-aniline (69) 
To a solution of hydrochloric acid was added aniline (17.0 mg, 0.1828 mmol). 
The resulting ammonium solution salt was cooled to 0~5 °C and to this was gradually 
added NaNO2 (18.92 mg, 0.2742 mmol) and stirred for 2 h. To the reaction mixture was 
added aniline (17.0 mg, 0.1828 mmol). The reaction mixture was then allowed to come 
up to room temperature and stirred for 10 min. To the mixture was then added NaHCO3 
(aqueous solution, 1 M; until pH = 8~9). The precipitates were extracted with CH2Cl2, 
concentrated under vacuum and subjected to flash column chromatography (100 % 
CH2Cl2) yielding 69 (20.0 mg, 56 %) as a reddish solid.   
 
1H NMR: δ = 7.85-7.80 (m, 4H), 7.50 (m, 2H), 7.42 (m, 1H), 6.75(m, 2H) ppm.  Mass 
calcd. for [M] 197.10, found (ES) [M] 197. 
 
 
p-(m-tolyldiazenyl)-m-toluidine (70)  
To a solution of hydrochloric acid was added m-toluidine (20.0 mg, 0.1866 
mmol). The resulting ammonium solution salt was cooled to 0~5 °C and to this was 
gradually added NaNO2 (20.00 mg, 0.2899 mmol) and stirred for 2 h. To the reaction 
mixture was added m-toluidine (20.0 mg, 0.1866 mmol). The reaction mixture was then 
allowed to come up to room temperature and stirred for 10 min. To the mixture was then 
added NaHCO3 (aqueous solution, 1 M; until pH = 8~9). The precipitates were extracted 
with CH2Cl2, concentrated under vacuum and subjected to flash column chromatography 
(100 % CH2Cl2) yielding 70 (6.3 mg, 15 %) as a reddish solid.   
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1H NMR: δ = 7.66 (m, 3H), 7.37 (m, 1H), 7.22 (m, 1H), 6.59 (m, 1H), 6.55 (m, 1H), 2.67 
(s, 3H), 2.44 (s, 3H) ppm.  Mass calcd. for [M] 225.13, found (ES) [M] 225. 
 
 
Synthesis of picolinic carboxamides of aminodiazenes (II) 
 
N-[3-methyl-4-[(2-methylphenyl)diazenyl]phenyl]-2-pyridine carboxamide (52)  
To a solution of 2-picolinic acid (9.0 mg, 0.0732 mmol) in methylene chloride 
(CH2Cl2; 0.5 ml) was added dichlorotriphenylphosphorane (PPh3Cl2; 24.40 mg, 0.0732 
mmol) and a drop of N,N-diisopropylethylamine. After stirring at room temperature for 
30 min, the reaction mixture was added 66 (3.3 mg, 0.0146 mmol) and stirred for 1h. The 
resulting mixture was concentrated under vacuum and subjected to flash column 
chromatography (100 % CH2Cl2) yielding 52 (3.2 mg, 66 %) as a yellowish solid.   
 
1H NMR: δ = 8.65 (d, J = 4.0 Hz, 1H), 8.33 (d, J = 8.0 Hz, 1H ), 7.95 (t, J = 4.0 Hz, 1H), 
7.89 (s, 1H), 7.76 (d, J = 9.0 Hz, 1H), 7.66 (m, 2H), 7.52 (m, 1H), 7.34 (s, 2H), 7.29 (m, 
1H), 2.79 (s, 3H),  2.75 (s, 3H) ppm.  Mass calcd. for [M] 330.15, found (ES) [M] 330. 
 
 
N-[4-(2-methylphenyldiazenyl)phenyl]-2-pyridine carboxamide (53)  
To a solution of 2-picolinic acid (4.7 mg, 0.0379 mmol) in methylene chloride 
(CH2Cl2; 0.5 ml) was added dichlorotriphenylphosphorane (PPh3Cl2; 11.84 mg, 0.0355 
mmol) and a drop of diisopropylethylamine. After stirring at room temperature for 30 
min, the reaction mixture was added 67 (1.6 mg, 0.0076 mmol) and stirred for 1h. The 
resulting mixture was concentrated under vacuum and subjected to flash column 
chromatography (100 % CH2Cl2) yielding 53 (0.9 mg, 36 %) as a yellowish solid.   
 
1H NMR: δ = 8.67 (m, 1H), 8.64 (d, J = 9.0 Hz, 1H), 8.35 (m, 1H), 7.97 (t, J = 2.0 Hz, 
1H), 7.92 (m, 3H), 7.84 (d, J = 1.0 Hz, 1H), 7.54 (m, 3H), 7.48 (m, 1H), 2.55 (s, 3H) 
ppm.  Mass calcd. for [M] 316.13, found (ES) [M] 316. 
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N-[2-ethyl-4-[(2-methylphenyl)diazenyl]phenyl]-2-pyridine carboxamide (54)  
To a solution of 2-picolinic acid (5.9 mg, 0.0481 mmol) in methylene chloride 
(CH2Cl2; 0.5 ml) was added dichlorotriphenylphosphorane (PPh3Cl2; 11.83 mg, 0.0355 
mmol) and a drop of diisopropylethylamine. After stirring at room temperature for 30 
min, the reaction mixture was added 68 (2.3 mg, 0.0096 mmol) and stirred for 1h. The 
resulting mixture was concentrated under vacuum and subjected to flash column 
chromatography (100 % CH2Cl2) yielding 54 (2.8 mg, 88 %) as a yellowish solid.   
 
1H NMR: δ = 8.67 (d, J = 4.0 Hz, 1H), 8.62 (d, J = 8.5 Hz, 1H ), 8.35 (d, J = 8.0 Hz, 1H 
), 7.96 (t, J = 7.5 Hz, 1H), 7.91 (m, 2H), 7.87 (m, 1H), 7.53 (m, 1H), 7.39-7.33 (m, 2H), 
7.30-7.25 (m, 1H), 2.92 (q, J = 7.5 Hz, 2H), 2.73 (s, 3H),  1.43 (t, J = 7.5 Hz, 3) ppm.  
Mass calcd. for [M] 344.16, found (ES) [M] 344. 
 
 
N-(4-phenyldiazenylphenyl)-2-pyridine carboxamide (55)  
To a solution of 2-picolinic acid (20.9 mg, 0.1698 mmol) in methylene chloride 
(CH2Cl2; 0.5 ml) was added dichlorotriphenylphosphorane (PPh3Cl2; 49.55 mg, 0.1487 
mmol) and a drop of diisopropylethylamine. After stirring at room temperature for 30 
min, the reaction mixture was added 69 (6.7 mg, 0.0340 mmol) and stirred for 1h. The 
resulting mixture was concentrated under vacuum and subjected to flash column 
chromatography (100 % CH2Cl2) yielding 55 (6.1 mg, 57 %) as a yellowish solid.   
 
1H NMR: δ = 8.64 (d, J = 5.5 Hz, 1H), 8.33 (d, J = 8.0 Hz, 1H), 8.01-7.90 (m, 7H), 7.51 
(m, 3H), 7.46 (m, 1H) ppm.  Mass calcd. for [M] 302.12, found (ES) [M] 302. 
 
 
N-[3-methyl-4-[(3-methylphenyl)diazenyl]phenyl]-2-pyridine carboxamide (56)  
To a solution of 2-picolinic acid (5.7 mg, 0.0522 mmol) in methylene chloride 
(CH2Cl2; 0.5 ml) was added dichlorotriphenylphosphorane (PPh3Cl2; 15.53 mg, 0.0466 
mmol) and a drop of diisopropylethylamine. After stirring at room temperature for 30 
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min, the reaction mixture was added 70 (2.1 mg, 0.0093 mmol) and stirred for 1h. The 
resulting mixture was concentrated under vacuum and subjected to flash column 
chromatography (100 % CH2Cl2) yielding 56 (2.8 mg, 87 %) as a yellowish solid.   
 
1H NMR: δ = 8.64 (d, J = 4.0 Hz, 1H), 8.33 (d, J = 8.0 Hz, 1H ), 7.95 (t, J = 5.5 Hz, 1H), 
7.90 (s, 1H), 7.74 (m, 3H), 7.65 (d, J = 9.0 Hz, 1H), 7.52 (m, 1H), 7.41 (m, 1H), 7.28 (m, 
1H), 2.78 (s, 3H),  2.47 (s, 3H) ppm.  Mass calcd. for [M] 330.15, found (ES) [M] 330. 
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CHAPTER 5 PROTAC BASED ON THE SYNTHETIC LIGAND 
 
 
5.1 Introduction 
 
Based on the positional scanning studies, N-[2-methyl-4-[(2-methylphenyl) 
diazenyl]phenyl]-2-pyridine carboxamide (36) was chosen as an optimal ligand to be 
used for the  development of PROTAC.  Since compound 35 does not have an 
appropriate handle (functional group) to link to the E3 ligase recognition motif, the 
structure was derivatized to introduce a ‟handle‟.  In this chapter, the effort for the 
functionalization of the compound 36 and the synthesis of PROTAC based on the 
synthetic structure is described.  The biological activities of PROTACs are evaluated 
herein as well.  
 
 
5.2 Synthesis and biological evaluation of PROTAC4 
 
First, it was designed to introduce a carboxylic acid functional group at the methyl 
group of A-ring.  The carboxylic acid residue was expected to be useful for coupling with 
a amine-containing linker, which then can be linked to the E3 ligase recognition motif.  
 
Figure 5.1 Synthesis of PROTAC4 
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To this end, 2-Aminophenylbutyric acid was activated by diazotization and then 
coupled to a 2-methylaniline via an electrophilic addition yielding 72.  The third ring 
moiety was coupled to the resulted aniline to provide 73 as proposed.  The resulting 
carboxylic acid was used to couple with the peptide moiety to give a fully assembled 
PROTAC.  The treatment of fully assembled PROTAC with neat TFA yielded 
PROTAC4 (74). 
The PROTAC4 was tested for AHR antagonistic activity using a luciferase 
reporter assay.  Although PROTAC4 did not exhibit good AHR antagonistic activity 
(Figure 5.2 A), PROTAC4 was further tested whether it induces the degradation of AHR.  
Contrary to the reporter assay resultPROTAC4 apparently displayed modest antagonistic 
activity targeting AHR in terms of the transcription of downstream gene.  Specifically, 
the effect of PROTAC4 on the mRNA level of XRE-regulated gene, CYP1A1, was 
investigated.  The result indicated that the treatment of PROTAC4 attenuated TCDD-
induced up-regulation of CYP1A1 transcription (Figure 5.2 B).  For another XRE-
regulated gene, CYP1B1, PROTAC4 diminished the TCDD-induced up-regulation of 
CYP1B1 transcription (Figure 5.2 C).  These results indicate that PROTAC4, to a certain 
extent, suppresses the transcription of downstream genes such as CYP1A1 and CYP1B1, 
though the result from the luciferase assay did not confirm the antagonistic activity of 
PROTAC4.  The possibility that this effect is due to the decreased level of AHR was 
ruled out as the treatment of PROTAC4 did not change AHR transcription in the presence 
or absence of TCDD (Figure 5.2 D and E). 
In conclusion,, the effect of PROTAC4 appears to be limited to the suppression of 
the TCDD-induced up-regulation of XRE-regulated luciferase. In addition, PROTAC4 
modestly attenuated the TCDD-induced transcription of downstream genes.  Taken all 
together, it appears that PROTAC4 is a weak antagonist of AHR signaling pathway 
without agonistic potency. 
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Figure 5.2 The Biological activity of PROTAC4  
A) PROTAC4 did not block TCDD-induced luciferase activity. HepG2 cells were 
transfected with human CYP1A1 promoter coupled luciferase gene construct (HepG2-
p450luc) and pre-treated either DMSO alone or with the compounds (10 nM to 10 μM).  
After 1hr, TCDD (1nM) was added. 4hr after TCDD, the cells were harvested, activities 
were measured.  B) PROTAC4 blocked the TCDD-induced transcription of CYP 1A1 
gene.  The NHK cells were treated with PROTAC4 (50 M), harvested at the 16 hr time 
point and then subjected to RT real time PCR analysis.  C) PROTAC4 blocked the 
TCDD-induced transcription of CYP1B1 gene.  The NHK cells were treated with 
PROTAC4 (50 M), harvested at the 16 hr time point and then subjected to RT real time 
PCR analysis.  D) PROTAC4 did not look affecting on the mRNA level of AHR at any 
given concentration.  The NHK cells were treated with increasing concentrations of 
PROTAC4 (5 M, 10 M and 50 M), harvested at the 16 hr time point and then 
subjected to RT real time PCR analysis.  E) Neither PROTAC4 nor TCDD appear to 
affect on the mRNA level of AHR.  The NHK cells were treated with PROTAC4 (10 
M), harvested at the 16 hr time point and then subjected to RT real time PCR analysis. 
These assays were performed by Eun-Young Choi, Ph.D. under the direction of Hollie I. 
Swanson Ph.D.  This data are not statistically analyzed 
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5.3 C ring-linked PROTACs 
 
 Despite the apparent inhibitory activity of PROTAC4 on the transcription of 
natural XRE-regulated genes, the XRE-regulated luciferase activity was not diminished 
by PROTAC4.  Thus, it was thought to be ideal to prepare optimum PROTACs, Given 
the difficulties of preparing the intermediates of PROTAC4, the introduction of a 
functional group at other position was examined to prepare optimum PROTAC with 
varying linker lengths. 
 
 
 
Figure 5.3 Synthetic scheme of C ring linked PROTACs 
 
 Thus, compound 35 was further derivatized to give a three-ring compound with a 
hydroxyl group on C-ring. It is important to note that a critical residue, 5-hydroxyl-2-
picolinic acid, is readily available.  To optimize the length of spacer that connects E3 
ligase to AHR, the hydroxyl group of 75 was derivatized using linker residue such as 
methyl-bromopentanoate (77), methyl-bromoundecanoate (78), and methyl-
bromohexadecanoate (79).  These resulting esters were then hydrolyzed under basic 
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condition unleashing the carboxylic group.  The carboxylic acids were coupled to E3 
ligase recognition motif (21) or glycine-attached E3 ligase recognition motif (degron 
peptide; 84) yielding fully assembled PROTACs.  The resulting PROTACs were then 
treated with neat TFA to remove t-butyl group from tyrosine residue of HIF-1a 
pentapeptide yielding PROTACs (85~90) with varying lengths of spacer (Figure 5.3).  
The structures of C ring-linked PROTACs were described in Figure 5.4. The PROTACs 
coupled through 5-hydroxyl group on the C ring was tested for their activity. 
 
 
Figure 5.4 C Ring linked PROTACs with various spacer lengths. 
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The activity of PROTACs was evaluated using the TCDD-induced luciferase 
activity in cultured cells.  The PROTACs coupled through 5-hydroxyl group on the C 
ring did not exhibit the ability to block TCDD-induced activation of AHR.  The 
differences among the activity of PROTACs were hardly observed (Data not shown).  
Hence, it appears that C ring has no tolerance for derivatization.  
 
 
 
 
Figure 5.5 The effect of PROTAC8 on the cellular level of AHR.   
A) DMSO (0.01 %), TCDD (1 nM) or PROTAC8 (1 M, 10 M and 25 M) were treated 
to MCF-7 cells or HaCaT cells for 72 hours. After harvesting, the cell lysates were 
subjected to western blot analysis.  B) The HaCaT cells were treated with DMSO (0.01 
%), TCDD (1 nM) and PROTAC8 (10 M) for the period indicated.  After harvesting, the 
cell lysates were subjected to western blot analysis. These western blot assays were 
performed by Eun-Young Choi, Ph.D. under the direction of Hollie I. Swanson Ph.D. 
  
 
Next, we questioned whether the PROTACs are able to induce the degradation of 
AHR.  Based on the previous studies investigating the correlation between linker length 
and PROTAC activity, PROTAC8 which has 15 atoms linker was selected to further 
examine its ability to induce the degradation of AHR.  However, PROTAC8 did not 
induce AHR degradation even after a 3-day incubation (Figure 5.4 A).  To rule out the 
possibility that the 72 hours time point was not optimum for the degradation of AHR, the 
effect of PROTAC8 was investigated at different time points but no AHR degradation 
could be observed. 
84 
 
5.4 Discussion 
 
 The PROTAC4 based on the synthetic ligand was successfully prepared through 
coupling the compound 36 to E3 ligase recognition motif through A ring and subjected to 
assessment of biological activity.  In the meantime, the intermediate, which has 
carboxylic acid handle on the 2-methyl position, was proposed to be further derivatized 
for the preparation of other PROTACs with longer linkers.  However, the zwitter-ionic 
intermediate caused several problems in the purification and synthetic strategy resulting 
in extremely low overall productivity.  The protection of the carboxylic acid moiety was 
largely limited, since the electrophilic addition coupling between A and B rings was 
designed to be performed in acidic condition (pH < 1).  Moreover, the next coupling 
reaction with picolinic acid was affected by the presence of an active carboxylic acid at 
the end of the handle causing a substantial side reaction and a low yield. 
 Therefore, the ligand structure was proposed to be functionalized on C ring for 
linker coupling for the next series of PROTACs were prepared of different linker length.  
With the benefit of a readily available building block, 5-hydroxy-2-picolinic acid, the 
ligand structure of 36 was functionalized on C ring with hydroxyl group.  Subsequently, 
the C ring coupled PROTACs with various lengths of linker were successfully prepared 
and subjected to biological evaluations in order to figure out the optimal linker length for 
PROTACs targeting AHR.  
 The results from the biological assessments informed that all the C-ring-coupled 
PROTACs with varying linker length are inactive either to block the TCDD-induced 
activation of AHR or to induce the degradation of AHR at the given concentrations and 
time points.  These PROTACs are undergoing further investigation of the presumed 
effect of PROTAC8.  However, it is possible that chemical modification of C ring may 
cause the loss of interaction with AHR.  Hence, it is suggested to shift onto the further 
functionalization on the other position leading to the development of different types of 
PROTACs.  
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5.5 Syntheses of PROTACs 
 
 
p-[o-(3-carboxylpropylphenyl)diazenyl]-o-toluidine (72) 
To an aqueous solution of hydrochloric acid (2 N, 0.25 ml) was added 2-
aminophenylbutyric acid, hydrochloride (20 mg, 92.73 mmol).  The resulting solution of 
amine salt was cooled to 0~5 °C and to this was gradually added NaNO2 (41.65 mg, 0.6 
mmol) and stirred for 2 h. To the reaction mixture was added o-toluidine (0.99 mg, 92.73 
mmol).  The reaction mixture was then allowed to come up to room temperature and 
stirred for 10 min.  To the mixture was then added NaHCO3 (aqueous solution, 1 M; until 
pH = 8~9).  The precipitates were extracted with CH2Cl2, concentrated under vacuum and 
subjected to flash column chromatography (100 % CH2Cl2).  The resulting product was 
further purified by prep-HPLC (waters 600) yielding 72 (2.1 mg, 7.6 %) as a reddish 
solid.  
 
1H NMR: δ = 7.71 (d, J = 7.5 Hz, 2H), 7.57 (dd, Ja = 7.5 Hz, Jb = 1.0 Hz, 1H), 7.29 (m, 
2H), 7.25 (m, 1H), 6.46 (dd, Ja = 8.0 Hz, Jb = 1.0 Hz, 1H), 2.68 (s, 3H), 2.24 (s, 3H) ppm.  
 
 
N-[2-methyl-4-[(2-(3-carboxylpropyl)-phenyl)diazenyl]phenyl]-2-pyridinecarboxamide 
(73) 
To a solution of 2-picolinic acid (3.3 mg, 0.0269 mmol) in methylene chloride 
(CH2Cl2; 0.5 ml) was added dichlorotriphenylphosphorane (PPh3Cl2; 8.0 mg, 0.0269 
mmol) and a drop of DIPEA.  After stirring at room temperature for 30 min, the reaction 
mixture was added 72 (2.1 mg, 0.0071 mmol) and stirred for 1h.  The resulting mixture 
was concentrated under vacuum and subjected to flash column chromatography (100 % 
CH2Cl2) yielding 73 (1.2 mg, 46 %) as a yellowish solid.  
 
1H NMR: δ = 8.67 (d, J = 4.5 Hz, 1H), 8.63 (d, J = 9.0 Hz, 1H),  8.36 (d, J = 8.1 Hz, 1H), 
7.98-7.88 (m, 2H), 7.84 (s, 1H),  7.64 (d, J = 8.4 Hz, 1H), 7.54 (m, 1H) 7.36 (m, 2H), 
7.30 (m, 1H), 3.16 (m, 2H), 2.80 (s, 2H), 2.26 (s, 3H), 2.04 (m, 2H) ppm.  Mass calcd. for 
[M] 402.17, found (ES) [M] 402. 
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PROTAC4 (74) 
To a solution of 73 (1.2 mg, 0.0030 mmol) in methylene chloride (CH2Cl2; 0.5 
ml) was added HBTU (3.4 mg, 0.0090 mmol), HOBt (1.4 mg, 0.0090 mmol), DIPEA 
(3.2 mg, 0.0250 mmol) and E3 ubiquitin ligase recognition peptide (H2N-Leu-Ala-Pro
OH
-
Tyr
t-butyl
-Ile-OBn ; 6.6 mg, 0.0090 mmol).  After stirring at room temperature for 2 h, the 
resulting mixture was concentrated under vacuum and subjected to flash column 
chromatography (CH2Cl2:MeOH = 9:1) to yield a fully assembled product (1.8 mg, 53 %) 
as a yellowish solid.   
 
1H NMR: δ = 8.67 (bs, 1H), 8.51 (bs, 1H), 8.31 (bs, 1H), 7.94 (m, 1H), 7.82 (m, 2H), 
7.63 (m, 1H), 7.53 (m, 1H), 7.40-7.27 (m, 8H), 7.02 (m, 2H), 6.81 (m, 2H), 5.17-5.12 (m, 
2H), 4.60 (m, 2H), 4.42 (m, 4H), 3.52 (m, 1H), 3.35 (m, 1H), 3.17 (m, 2H), 3.05 (m, 1H), 
2.95 (m, 1H), 2.81 (s, 4H), 2.53 (s, 4H), 2.35 (m, 5H), 2.06 (m, 2H), 1.09 (m, 2H), 1.68-
1.45 (m, 3H), 1.25 (m, 1H), 1.13 (m, 2H), 0.96-0.72 (m, 1H) ppm.   
 
To a solution of the fully assembled product (1.8 mg, 0.0016 mmol) in CH2Cl2 
(0.2 ml) was added trifluoroacetic acid (100 µl, 0.87 mmol) at room temperature for 15 
min to deprotect t-butyl residue of tyrosine within the fully assembled compound. 
Subsequently, the concentrated mixture was dried under high vacuum to remove 
trifluoroacetic acid. The resulting crude product was subjected to flash column 
chromatography (CH2Cl2/MeOH, 9:1) to yield 74 (1.7 mg, 90 %) as a yellowish solid.   
 
1
H NMR: δ = 8.67 (bs, 1H), 8.51 (bs, 1H), 8.31 (bs, 1H), 7.94 (m, 1H), 7.82 (m, 2H), 
7.63 (m, 1H), 7.53 (m, 1H), 7.40-7.27 (m, 8H), 7.02 (m, 2H), 6.81 (m, 2H), 5.17-5.12 (m, 
2H), 4.60 (m, 2H), 4.42 (m, 4H), 3.52 (m, 1H), 3.35 (m, 1H), 3.17 (m, 2H), 3.05 (m, 1H), 
2.95 (m, 1H), 2.81 (s, 4H), 2.53 (s, 4H), 2.35 (m, 5H), 2.06 (m, 2H), 1.09 (m, 2H), 1.68-
1.45 (m, 3H), 1.25 (m, 10H), 1.13 (m, 2H), 0.96-0.72 (m, 1H) ppm.   
 
Mass calcd. for [M] 1065.53, found (MALDI) [M] 1066. 
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Figure 5.6 Mass spectrum for PROTAC4 
 
 
N-[2-methyl-4-[(2-methylphenyl)azo]phenyl]-6-hydroxypyridine-2-carboxamide (76) 
To a solution of 6-hydroxypyridine-2-carboxylic acid (75, 30.9 mg, 0.2219 mmol) 
in methylene chloride (CH2Cl2; 1 ml) was added dichlorotriphenylphosphorane (PPh3Cl2; 
74.0 mg, 0.2219 mmol) and a drop of diisopropylethylamine.  After stirring at room 
temperature for 30 min, the reaction mixture was added 57 (10.0 mg, 0.0444 mmol) and 
stirred for 1h.  The resulting mixture was concentrated under vacuum and subjected to 
flash column chromatography (CH2Cl2).  The resulting product was further purified by 
prep-HPLC (waters 600) yielding 76 (14.2 mg, 92 %) as a yellowish solid.   
 
1H NMR: δ = 8.67 (d, J = 4.5 Hz, 1H), 8.63 (d, J = 9.0 Hz, 1H),  8.36 (d, J = 8.1 Hz, 1H), 
7.98-7.88 (dq, Ja = 1.6 Hz, Jb = 7.5 Hz, 2H ), 7.84 (s, 1H),  7.64 (d, J = 8.4 Hz, 1H), 7.54 
(m, 1H) 7.36 (m, 2H), 7.30 (m, 1H), 2.74 (s, 3H), 2.56 (s, 3H) ppm.  Mass calcd. for [M] 
346.14, found (ES) [M] 346. 
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Synthesis of 80 
To a solution of 76 (4.0 mg, 0.0116 mmol) in methylene chloride (CH2Cl2; 1 ml) 
was added K2CO3 (7.0 mg, 0.0259 mmol) and methyl-5-bromovalerate (77, 4.6 mg, 
0.0232 mmol).  After stirring at room temperature for 15 h, the resulting mixture was 
concentrated under vacuum and subjected to flash column chromatography 
(CH2Cl2/MeOH, 95:5) yielding an methyl ester (4.8 mg, 84 %) as a yellowish solid. 
 
1
H NMR: δ = 8.57 (d, J = 8.5 Hz, 1H), 7.86 (m, 2H), 7.75 (m, 2H), 7.56 (d, J = 8.0 Hz, 
1H), 7.27 (s, 2H), 7.20 (s, 1H), 6.90 (d, J = 8.5 Hz, 1H), 4.42 (t, J = 6.0 Hz, 2H), 3.69 (s, 
3H), 2.73 (s, 3H), 2.52 (s, 3H) 2.44 (t, J = 7.0 Hz, 2H), 1.91-1.89 (m, 4H) ppm.  Mass 
calcd. for [M] 460.21, found (ES) [M] 460. 
 
To a solution of the ester in THF/H2O, 3:1(1 ml) was added LiOH (5.4mg, 
0.2237mmol). After stirring at room temperature for 15 h, the resulting mixture was 
poured into H2O with cold 1N HCl and extracted with CH2Cl2. The organic layers were 
combined, washed with brine, dried over Na2SO4, filtered, concentrated and dried under 
vacuum to yield 80 (4.6 mg, 99 %) as a yellowish solid.   
 
 
Synthesis of 84 
To a solution of E3 ligase recognition motif (21, 20.0 mg, 0.0271 mmol) was 
added HBTU (15.4 mg, 0.0407 mmol), HOBt (6.2 mg, 0.0407 mmol), 
diisopropylethylamine (14.2 mg, 0.1100 mmol) and Fmoc-Gly-OH (83, 9.1 mg, 
0.03252).  After stirring at room temperature for 2 h, the resulting mixture was 
concentrated under reduced pressure and subjected to flash column choromatography 
(CH2Cl2/MeOH, 95:5). The resulting compound was treated with a 20% solution of 
piperidine in DMF (0.7 ml, v/v) to deprotect fluorenylmethyloxycarboxyl group on amine 
group. After 15 min the resulting mixture was  concentrated under vacuum and subjected 
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to flash column choromatography (CH2Cl2/MeOH, 95:5) yielding 84 (20.0 mg, 93 %) as 
a white solid.   
 
 
Synthesis of 81 
To a solution of 76 (4.0 mg, 0.0116 mmol) in methylene chloride (CH2Cl2; 1 ml) 
was added K2CO3 (7.0 mg, 0.0259 mmol) and methyl-11-bromoundecanoate (78, 6.4 mg, 
0.0232 mmol).  After stirring at room temperature for 15 h, the resulting mixture was 
concentrated under vacuum and subjected to flash column chromatography 
(CH2Cl2/MeOH, 95:5) yielding an methyl ester (5.5 mg, 87 %) as a yellowish solid.   
 
1
H NMR: δ = 8.66 (d, J = 8.5 Hz, 1H), 7.91 (m, 2H), 7.82 (m, 2H), 7.63 (d, J = 8.0 Hz, 
1H), 7.34 (s, 2H), 7.27 (s, 1H), 6.96 (d, J = 8.5 Hz, 1H), 4.38 (t, J = 6.0 Hz, 2H), 3.76 (s, 
3H), 2.73 (s, 3H), 2.52 (s, 3H), 2.33 (m, 3H), 1.87 (m, 2H), 1.63(m 3H), 1.48 (m, 2H), 
1.38-1.25 (m, 8H) ppm.  Mass calcd. for [M] 544.30, found (ES) [M] 544. 
 
To a solution of the ester in THF/H2O, 3:1(1 ml) was added LiOH (5.4mg, 
0.2237mmol). After stirring at room temperature for 15 h, the resulting mixture was 
poured into H2O with cold 1N HCl and extracted with CH2Cl2. The organic layers were 
combined, washed with brine, dried over Na2SO4, filtered, concentrated and dried under 
vacuum to yield 81 (5.3 mg, 98 %) as a yellowish solid.   
 
 
Synthesis of 82 
To a solution of 76 (4.0 mg, 0.0116 mmol) in methylene chloride (CH2Cl2; 1 ml) 
was added K2CO3 (6.8 mg, 0.0259 mmol) and methyl-16-bromohexadecanoate (79, 4.1 
mg, 0.0232 mmol).  After stirring at room temperature for 15 h, the resulting mixture was 
concentrated under vacuum and subjected to flash column chromatography 
(CH2Cl2/MeOH, 95:5) yielding an methyl ester (6.8 mg, 95 %) as a yellowish solid.   
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1
H NMR: δ = 8.66 (d, J = 8.5 Hz, 1H), 7.91 (m, 2H), 7.82 (m, 2H), 7.63 (d, J = 8.0 Hz, 
1H), 7.34 (s, 2H), 7.27 (s, 1H), 6.96 (d, J = 8.5 Hz, 1H), 4.38 (t, J = 6.0 Hz, 2H), 3.76 (s, 
3H), 2.73 (s, 3H), 2.52 (s, 3H), 2.33 (m, 3H), 1.87 (m, 2H), 1.63(m 3H), 1.48 (m, 2H), 
1.38-1.25 (m, 18H) ppm.  Mass calcd. for [M] 614.38, found (ES) [M] 614. 
 
To a solution of the ester in THF/H2O, 3:1(1 ml) was added LiOH (5.4mg, 
0.2237mmol). After stirring at room temperature for 15 h, the resulting mixture was 
poured into H2O with cold 1N HCl and extracted with CH2Cl2. The organic layers were 
combined, washed with brine, dried over Na2SO4, filtered, concentrated and dried under 
vacuum to yield 82 (6.6 mg, 98 %) as a yellowish solid.   
 
 
PROTAC5 (85) 
To a solution of 80 (1.0 mg, 0.0022 mmol) in methylene chloride (CH2Cl2; 0.5 
ml) was added HBTU (1.3 mg, 0.0033 mmol), HOBt (0.5 mg, 0.0033 mmol), DIPEA 
(1.4 mg, 0.0110 mmol) and E3 ligase recognition motif (2.4 mg, 0.0033 mmol).  After 
stirring at room temperature for 2 h, the resulting mixture was concentrated under 
vacuum and subjected to flash column chromatography (CH2Cl2:MeOH = 9:1) to yield a 
fully assembled product (2.1 mg, 82 %) as a yellowish solid.   
 
1
H NMR: δ = 8.57 (d, J = 8.5 Hz, 1H), 7.86 (m, 2H), 7.75 (m, 2H), 7.56 (d, J = 8.0 Hz, 
1H), 7.35 (m, 5H), 7.27 (s, 2H), 7.20 (s, 1H), 7.08 (d, J = 8.5 Hz, 2H), 6.90 (m, 3H), 5.13 
(s, 2H), 4.63-4.42 (m, 7H), 3.09 (m, 1H), 2.89 (m, 1H), 2.73 (s, 3H), 2.52 (s, 3H) 2.33 
(m, 2H), 1.93 (m, 2H), 1.91-1.89 (m, 4H) 1.55 (m, 2H), 1.45 (m, 1H), 1.28 (s, 9H), 1.25 
(s, 6H), 1.16 (m, 1H), 1.05-0.83 (m, 12H) ppm.  
 
To a solution of the fully assembled product (2.1 mg, 0.0018 mmol) in CH2Cl2 
(0.2 ml) was added trifluoroacetic acid (100 µl, 0.87 mmol) at room temperature for 15 
min to deprotect t-butyl residue of tyrosine within the fully assembled compound. 
Subsequently, the concentrated mixture was dried under high vacuum to remove 
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trifluoroacetic acid. The resulting crude product was subjected to flash column 
chromatography (CH2Cl2/MeOH, 9:1) to yield 85 (2.0 mg, 100 %) as a yellowish solid.   
 
1
H NMR: δ = 8.57 (d, J = 8.5 Hz, 1H), 7.86 (m, 2H), 7.75 (m, 2H), 7.56 (d, J = 8.0 Hz, 
1H), 7.35 (m, 5H), 7.27 (s, 2H), 7.20 (s, 1H), 7.08 (d, J = 8.5 Hz, 2H), 6.90 (m, 3H), 5.13 
(s, 2H), 4.63-4.42 (m, 7H), 3.09 (m, 1H), 2.89 (m, 1H), 2.73 (s, 3H), 2.52 (s, 3H) 2.33 
(m, 2H), 1.93 (m, 2H), 1.91-1.89 (m, 4H) 1.55 (m, 2H), 1.45 (m, 1H), 1.25 (s, 6H), 1.18 
(m, 1H), 1.00-0.84 (m, 12H) ppm.  
 
Mass calcd. for [M] 1109.56, found (MALDI) [M] 1110. 
 
Figure 5.7 Mass spectrum for PROTAC5 
 
 
PROTAC6 (86) 
To a solution of 80 (1.0 mg, 0.0022 mmol) in methylene chloride (CH2Cl2; 0.5 
ml) was added HBTU (1.3 mg, 0.0033 mmol), HOBt (0.5 mg, 0.0033 mmol), DIPEA 
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(1.4 mg, 0.0110 mmol) and 84 (2.6 mg, 0.0033 mmol).  After stirring at room 
temperature for 2 h, the resulting mixture was concentrated under vacuum and subjected 
to flash column chromatography (CH2Cl2:MeOH = 9:1) to yield a fully assembled 
product (2.1 mg, 78 %) as a yellowish solid.   
 
1
H NMR: δ = 8.57 (d, J = 8.5 Hz, 1H), 7.86 (m, 2H), 7.75 (m, 2H), 7.56 (d, J = 8.0 Hz, 
1H), 7.35 (m, 5H), 7.27 (s, 2H), 7.20 (s, 1H), 7.08 (d, J = 8.5 Hz, 2H), 6.90 (m, 3H), 5.13 
(s, 2H), 4.42 (m, 9H), 3.69 (s, 3H), 3.09 (m, 1H), 2.89 (m, 1H), 2.73 (s, 3H), 2.52 (s, 3H) 
2.44 (t, J = 7.0 Hz, 2H), 1.93 (m, 2H), 1.91-1.89 (m, 4H) 1.55 (m, 2H), 1.45 (m, 1H), 
1.28 (s, 9H), 1.25 (s, 6H), 1.17 (m, 1H), 1.09-0.85 (m, 12H) ppm.   
 
To a solution of the fully assembled product (2.1 mg, 0.0017 mmol) in CH2Cl2 
(0.2 ml) was added trifluoroacetic acid (100 µl, 0.87 mmol) at room temperature for 15 
min to deprotect t-butyl residue of tyrosine within the fully assembled compound. 
Subsequently, the concentrated mixture was dried under high vacuum to remove 
trifluoroacetic acid. The resulting crude product was subjected to flash column 
chromatography (CH2Cl2/MeOH, 9:1) to yield 86 (2.0 mg, 100 %) as a yellowish solid.   
 
1
H NMR: δ = 8.57 (d, J = 8.5 Hz, 1H), 7.86 (m, 2H), 7.75 (m, 2H), 7.56 (d, J = 8.0 Hz, 
1H), 7.35 (m, 5H), 7.27 (s, 2H), 7.20 (s, 1H), 7.08 (d, J = 8.5 Hz, 2H), 6.90 (m, 3H), 5.13 
(s, 2H), 4.42 (m, 9H), 3.69 (s, 3H), 3.09 (m, 1H), 2.89 (m, 1H), 2.73 (s, 3H), 2.52 (s, 3H) 
2.44 (t, J = 7.0 Hz, 2H), 1.93 (m, 2H), 1.91-1.89 (m, 4H) 1.55 (m, 2H), 1.45 (m, 1H), 
1.25 (s, 6H), 1.17 (m, 1H), 1.10-0.85 (m, 12H) ppm.   
 
Mass calcd. for [M] 1166.58, found (MALDI) [M] 1166.71. 
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Figure 5.8 Mass spectrum for PROTAC6 
 
 
PROTAC7 (87) 
To a solution of 81 (1.0 mg, 0.0022 mmol) in methylene chloride (CH2Cl2; 0.5 
ml) was added HBTU (1.3 mg, 0.0030 mmol), HOBt (0.5 mg, 0.0030 mmol), DIPEA 
(1.4 mg, 0.0110 mmol) and E3 ligase recognition motif (2.2 mg, 0.0030 mmol).  After 
stirring at room temperature for 2 h, the resulting mixture was concentrated under 
vacuum and subjected to flash column chromatography (CH2Cl2:MeOH = 9:1) to yield a 
fully assembled product (2.2 mg, 90 %) as a yellowish solid.   
 
1
H NMR: δ = 8.66 (d, J = 8.5 Hz, 1H), 7.91 (m, 2H), 7.82 (m, 2H), 7.63 (d, J = 8.0 Hz, 
1H), 7.35 (m, 7H), 7.27 (s, 1H), 7.08 (d, J = 8.5 Hz, 2H), 6.96 (d, J = 8.5 Hz, 3H), 5.13 
(s, 2H), 4.40 (m, 7H), 3.76 (s, 3H), 3.09 (m, 1H), 2.89 (m, 1H), 2.73 (s, 3H), 2.52 (s, 3H), 
2.33 (m, 3H), 1.93 (m, 2H), 1.87 (m, 2H), 1.63(m 3H), 1.55 (m, 2H), 1.48 (m, 2H), 1.45 
(m, 1H), 1.38-1.24 (m, 23H), 1.17 (m, 1H), 0.83-1.00 (m, 12H) ppm. 
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To a solution of the fully assembled product (2.2 mg, 0.0017 mmol) in CH2Cl2 
(0.2 ml) was added trifluoroacetic acid (100 µl, 0.87 mmol) at room temperature for 15 
min to deprotect t-butyl residue of tyrosine within the fully assembled compound. 
Subsequently, the concentrated mixture was dried under high vacuum to remove 
trifluoroacetic acid. The resulting crude product was subjected to flash column 
chromatography (CH2Cl2/MeOH, 9:1) to yield 87 (2.1 mg, 100 %) as a yellowish solid.   
 
1
H NMR: δ = 8.66 (d, J = 8.5 Hz, 1H), 7.91 (m, 2H), 7.82 (m, 2H), 7.63 (d, J = 8.0 Hz, 
1H), 7.35 (m, 7H), 7.27 (s, 1H), 7.08 (d, J = 8.5 Hz, 2H), 6.96 (d, J = 8.5 Hz, 3H), 5.13 
(s, 2H), 4.40 (m, 7H), 3.76 (s, 3H), 3.09 (m, 1H), 2.89 (m, 1H), 2.73 (s, 3H), 2.52 (s, 3H), 
2.33 (m, 3H), 1.93 (m, 2H), 1.87 (m, 2H), 1.63(m 3H), 1.55 (m, 2H), 1.48 (m, 2H), 1.45 
(m, 1H), 1.38-1.24 (m, 14H), 1.17 (m, 1H), 0.83-1.00 (m, 12H) ppm. 
 
Mass calcd. for [M] 1193.65, found (MALDI) [M] 1193.81. 
 
 
Figure 5.9 Mass spectrum for PROTAC7 
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PROTAC8 (88) 
To a solution of 81 (1.1 mg, 0.0022 mmol) in methylene chloride (CH2Cl2; 0.5 
ml) was added HBTU (1.3 mg, 0.0030 mmol), HOBt (0.5 mg, 0.0030 mmol), DIPEA 
(1.4 mg, 0.0110 mmol) and 84 (2.6 mg, 0.0033 mmol).  After stirring at room 
temperature for 2 h, the resulting mixture was concentrated under vacuum and subjected 
to flash column chromatography (CH2Cl2:MeOH = 9:1) to yield a fully assembled 
product (2.1 mg, 73 %) as a yellowish solid.   
 
1
H NMR: δ = 8.66 (d, J = 8.5 Hz, 1H), 7.91 (m, 2H), 7.82 (m, 2H), 7.63 (d, J = 8.0 Hz, 
1H), 7.35 (s, 7H), 7.27 (s, 1H), 7.08 (d, J = 8.5 Hz, 2H), 6.96 (m, 3H), 5.13 (s, 2H), 4.40 
(m, 9H), 3.76 (s, 3H), 3.09 (m, 1H), 2.89 (m, 1H), 2.73 (s, 3H), 2.52 (s, 3H), 2.33 (m, 
3H), 1.93 (m, 2H), 1.87 (m, 2H), 1.63(m 3H), 1.55 (m, 2H), 1.47 (m, 3H), 1.38-1.25 (m, 
14H), 1.10-0.83 (m, 13H) ppm. 
 
To a solution of the fully assembled product (2.1 mg, 0.0017 mmol) in CH2Cl2 
(0.2 ml) was added trifluoroacetic acid (100 µl, 0.87 mmol) at room temperature for 15 
min to deprotect t-butyl residue of tyrosine within the fully assembled compound. 
Subsequently, the concentrated mixture was dried under high vacuum to remove 
trifluoroacetic acid. The resulting crude product was subjected to flash column 
chromatography (CH2Cl2/MeOH, 9:1) to yield 87 (2.0 mg, 100 %) as a yellowish solid.   
 
1
H NMR: δ = 8.66 (d, J = 8.5 Hz, 1H), 7.91 (m, 2H), 7.82 (m, 2H), 7.63 (d, J = 8.0 Hz, 
1H), 7.35 (s, 7H), 7.27 (s, 1H), 7.08 (d, J = 8.5 Hz, 2H), 6.96 (m, 3H), 5.13 (s, 2H), 4.40 
(m, 9H), 3.76 (s, 3H), 3.09 (m, 1H), 2.89 (m, 1H), 2.73 (s, 3H), 2.52 (s, 3H), 2.33 (m, 
3H), 1.93 (m, 2H), 1.87 (m, 2H), 1.63(m 3H), 1.55 (m, 2H), 1.47 (m, 3H), 1.38-1.25 (m, 
23H), 1.10-0.83 (m, 13H) ppm. 
 
Mass calcd. for [M] 1250.67, found (MALDI) [M] 1250.61. 
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Figure 5.10 Mass spectrum for PROTAC8 
 
 
PROTAC9 (89) 
To a solution of 82 (1.2 mg, 0.0020 mmol) in methylene chloride (CH2Cl2; 0.5 
ml) was added HBTU (1.3 mg, 0.0033 mmol), HOBt (0.5 mg, 0.0033 mmol), DIPEA 
(1.4 mg, 0.0110 mmol) and E3 ligase recognition motif (2.4 mg, 0.0033 mmol).  After 
stirring at room temperature for 2 h, the resulting mixture was concentrated under 
vacuum and subjected to flash column chromatography (CH2Cl2:MeOH = 9:1) to yield a 
fully assembled product (2.1 mg, 80 %) as a yellowish solid.   
 
1
H NMR: δ = 8.66 (d, J = 8.5 Hz, 1H), 7.91 (m, 2H), 7.82 (m, 2H), 7.63 (d, J = 8.0 Hz, 
1H), 7.35 (m, 7H), 7.27 (s, 1H), 7.08 (d, J = 8.5 Hz, 2H), 6.96 (m, 3H), 5.13 (s, 2H), 4.41 
(m, 7H), 3.76 (s, 3H), 3.09 (m, 1H), 2.89 (m, 1H), 2.73 (s, 3H), 2.52 (s, 3H), 2.33 (m, 
3H), 1.93 (m, 2H), 1.87 (m, 2H), 1.63(m 3H), 1.55 (m, 2H), 1.47 (m, 3H), 1.38-1.25 (m, 
24H), 1.12-0.83 (m, 13H) ppm. 
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To a solution of the fully assembled product (2.1 mg, 0.0016 mmol) in CH2Cl2 
(0.2 ml) was added trifluoroacetic acid (100 µl, 0.87 mmol) at room temperature for 15 
min to deprotect t-butyl residue of tyrosine within the fully assembled compound. 
Subsequently, the concentrated mixture was dried under high vacuum to remove 
trifluoroacetic acid. The resulting crude product was subjected to flash column 
chromatography (CH2Cl2/MeOH, 9:1) to yield 89 (1.8 mg, 89 %) as a yellowish solid.   
 
1
H NMR: δ = 8.66 (d, J = 8.5 Hz, 1H), 7.91 (m, 2H), 7.82 (m, 2H), 7.63 (d, J = 8.0 Hz, 
1H), 7.35 (m, 7H), 7.27 (s, 1H), 7.08 (d, J = 8.5 Hz, 2H), 6.96 (m, 3H), 5.13 (s, 2H), 4.41 
(m, 7H), 3.76 (s, 3H), 3.09 (m, 1H), 2.89 (m, 1H), 2.73 (s, 3H), 2.52 (s, 3H), 2.33 (m, 
3H), 1.93 (m, 2H), 1.87 (m, 2H), 1.63(m 3H), 1.55 (m, 2H), 1.47 (m, 3H), 1.38-1.25 (m, 
33H), 1.12-0.83 (m, 13H) ppm. 
 
Mass calcd. for [M] 1263.73, found (MALDI) [M] 1263.71. 
 
 
Figure 5.11 Mass spectrum for PROTAC9 
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PROTAC10 (90) 
To a solution of 82 (1.2 mg, 0.0020 mmol) in methylene chloride (CH2Cl2; 0.5 
ml) was added HBTU (1.3 mg, 0.0033 mmol), HOBt (0.5 mg, 0.0033 mmol), DIPEA 
(1.4 mg, 0.0110 mmol) and 84 (2.6 mg, 0.0033 mmol).  After stirring at room 
temperature for 2 h, the resulting mixture was concentrated under vacuum and subjected 
to flash column chromatography (CH2Cl2:MeOH = 9:1) to yield a fully assembled 
product (2.0 mg, 73 %) as a yellowish solid.   
 
1
H NMR: δ = 8.66 (d, J = 8.5 Hz, 1H), 7.91 (m, 2H), 7.82 (m, 2H), 7.63 (d, J = 8.0 Hz, 
1H), 7.35 (m, 7H), 7.27 (s, 1H), 7.08 (d, J = 8.5 Hz, 2H), 6.96 (m, 3H), 5.13 (s, 2H), 4.41 
(m, 9H), 3.76 (s, 3H), 3.09 (m, 1H), 2.89 (m, 1H), 2.73 (s, 3H), 2.52 (s, 3H), 2.33 (m, 
3H), 1.93 (m, 2H), 1.87 (m, 2H), 1.63(m 3H), 1.55 (m, 2H), 1.47 (m, 3H), 1.38-1.25 (m, 
33H), 1.12-0.83 (m, 13H) ppm. 
 
To a solution of the fully assembled product (2.0 mg, 0.0015 mmol) in CH2Cl2 
(0.2 ml) was added trifluoroacetic acid (100 µl, 0.87 mmol) at room temperature for 15 
min to deprotect t-butyl residue of tyrosine within the fully assembled compound. 
Subsequently, the concentrated mixture was dried under high vacuum to remove 
trifluoroacetic acid. The resulting crude product was subjected to flash column 
chromatography (CH2Cl2/MeOH, 9:1) to yield 90 (1.9 mg, 99 %) as a yellowish solid.   
 
1
H NMR: δ = 8.66 (d, J = 8.5 Hz, 1H), 7.91 (m, 2H), 7.82 (m, 2H), 7.63 (d, J = 8.0 Hz, 
1H), 7.35 (m, 7H), 7.27 (s, 1H), 7.08 (d, J = 8.5 Hz, 2H), 6.96 (m, 3H), 5.13 (s, 2H), 4.41 
(m, 9H), 3.76 (s, 3H), 3.09 (m, 1H), 2.89 (m, 1H), 2.73 (s, 3H), 2.52 (s, 3H), 2.33 (m, 
3H), 1.93 (m, 2H), 1.87 (m, 2H), 1.63(m 3H), 1.55 (m, 2H), 1.47 (m, 3H), 1.38-1.25 (m, 
24H), 1.12-0.83 (m, 13H) ppm. 
 
Mass calcd. for [M] 1320.75, found (MALDI) [M] 1320.81. 
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Figure 5.12 Mass spectrum for PROTAC10 
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CHAPTER 6  CONCLUSION 
 
6.1 Discussion 
 
AHR is a ligand-activated transcription factor regulating the expression of a 
number of genes by an agonist.  The AHR signaling pathway is triggered by the 
activation of the receptor.  In the traditional methodology, the study on a signaling 
pathway involves identification of the initiation signal.  The study also includes an 
understanding of the cellular events caused by the affected signal transduction and gene 
regulations.  For the AHR signaling pathway, the endogenous ligands that trigger the 
activation of signaling pathway are not yet well known and the corresponding function of 
the receptor is not yet fully understood.  Recent studies suggest that the role of AHR may 
not be limited to the classical role as a regulator of xenobiotic metabolism.  In addition, 
the findings that the AHR crosstalks with a number of other transcriptional factors further 
indicate the complexity of AHR signaling pathway.  To dissect these complex signaling 
networks, the functional modulators specific for each signaling molecule provide 
powerful molecular tools.  A number of potent AHR agonists are currently available for 
signaling studies.  However, most AHR antagonists previously identified also function as 
partial agonists, limiting their use as molecular probes. 
AHR binds to a large number of aromatic hydrocarbons of diverse.  In order to 
maintain an "inactive" conformation of the receptor while it is interacting with ligand, 
one of the major concerns was the structural flexibility of AHR antagonist.  It is because 
that the structures of strong AHR agonists are rigid and mono-planar in general, whereas 
those of newly identified antagonists are relatively flexible.  Taken together, it was 
hypothesized that a multi-planar and flexible aromatic structure may provide pure 
antagonistic activity.  Consistent with the hypothesis, a number of the flexible 
compounds developed in this study are pure antagonists. 
The use of chemical library for ligand moiety of PROTAC is anticipated to 
provide a potential platform for the systemic development of appropriate molecular 
probes for the wider applications.  In the present study, we hypothesized that AHR can be 
targeted though PROTAC approach.  Once apigenin based PROTAC provided the proof 
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of principle, we then constructed a small focused library based on CH-223191.  To this 
end, we optimized the ligand structure for antagonistic activity and prepared PROTACS 
based on the antagonist.  To the best of my knowledge, this is the first trial to develop a 
small molecule targeting a protein of interest via the combinatorial methodology of 
PROTAC and chemical library. 
 The overall goal of this study was the development of novel AHR antagonist 
without agonistic potency.  In accordance with the goal, a series of works were set forth 
as specific aims and performed.  The followings are the summary of the accomplishments 
and the general conclusions drawn based on the results. 
 
6.2 Summary 
1. The PROTAC based on apigenin was successfully synthesized. 
2. The PROTAC based on an exogenous ligand, apigenin, successfully induced 
degradation of AHR and effectively blocked TCDD-induced activation of AHR. 
3. A Chemical library based on the structure of CH-223191 was constructed and 
screened for AHR antagonistic activity. 
4. N-[2-Methyl-4-[(2-methylphenyl)diazenyl]phenyl]-2-pyridine carboxamide (36), 
N-[2-methyl-4-[(2-methylphenyl)diazenyl]phenyl]-2-pyrazine carboxamide (37) 
and N-[2-methyl-4-[(2-methylphenyl)diazenyl]phenyl]-2-furan carboxamide (31) 
were identified as antagonists of AHR. 
5. p-(p-tolyldiazenyl)-o-toluidine exhibited synergistic activity for AHR activation 
in concert with TCDD in prolonged incubation. 
6. The PROTACs based on the compound 36 was successfully prepared through A 
ring or C ring modification. 
7. The PROTACs based on synthetic structure did not exhibit antagonistic activity in 
the initial experimental condition. 
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6.3 Conclusions 
1. AHR can be targeted through the PROTAC approach. 
2. PROTAC based on apigenin (PROTAC2) induces degradation of AHR and 
suppresses TCDD-induced activation of AHR without agonistic activity. 
3. The structure of CH-223191 was optimized for AHR antagonistic activity by 
positional scanning identifying N-[2-Methyl-4-[(2-methylphenyl)diazenyl] 
phenyl]-2-pyridinecarboxamide (36) as the optimal AHR antagonist. 
4. PROTAC based on synthetic ligand showed a modest antagonistic activity. 
Further characterization and optimization may be required 
 
 
6.4. Future directions 
 
The process of the development of PROTAC generated a number of useful 
research tools for studying or probing AHR biology such as agonist and antagonists 
targeting AHR including the PROTACs.  Further, the findings and analyses described 
herein proposed a number of valuable insights that will likely be useful for further 
optimization of PROTACs targeting AHR.  
The two functional heads are the primary targets for the optimization.  In spite of 
optimization of the CH-223191 structure for antagonistic activity, we still do not have 
full understanding of the ligand structure required for pure antagonistic activity.  Since an 
increasing number of building blocks for each position are made available, the ligand 
structure can be optimized further.  On the other hand, the E3 ligase recognition motif 
moiety eliciting proteolysis is the key component for PROTAC development as well.  
This head has been evolved from diphospho-IκB fragment into E3 ligase recognition 
motif exhibiting excellent activity.  However, the PROTAC equipped with the small 
molecule, nutlin, has been reported, suggesting that non-peptidyl structures may also be 
useful in design of PROTACs.  The investigation on the linker length described herein 
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did not reveal the optimal distance.  Nonetheless, the linker moiety should be considered 
for improving the PROTAC activity since it serves as a spacer providing appropriate 
distance between two heads for the proper interaction. 
It is also suggested that the effect on the each stage of signaling pathway as 
shown in the study on apigenin based PROTAC be investigated.  In addition, the 
investigation on the specificity of future PROTACs is strongly suggested.  With the 
further efforts to develop PROTACs of higher potency, the PROTAC technology will be 
validated as a generally applicable chemical approach to biology. 
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